<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Medical Oncology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Medical Oncology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Medical+Oncology&t=Medical+Oncology&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 08:41:48 +0100</lastBuildDate>
        <item>
            <title>Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin’s lymphoma patients</title>
            <link>http://www.medworm.com/index.php?rid=5666797&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F85055473656832w7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of tumor-infiltrating T cell subsets in the prognosis of non-Hodgkin’s lymphoma (NHL) has previously been reported.
 In the present study, we investigated the prognostic significance of different T cell subsets in the peripheral blood of NHL
 patients. Immunophenotyping was performed on the peripheral blood samples of 45 patients with newly diagnosed B cell NHL using
 flow cytometry. The relationship between T cell subsets of CD4+, CD8+, CD3+CD25+, CD4+CD25+, CD4+CD25high [as T regulatory cells (T reg)], and the CD4/CD8 ratio with international prognostic index (IPI) and response to therapy
 was determined. The percentages of CD3+, CD4+, and CD8+&amp;nbsp;T cells in the peripheral blood of the patients were 49.1&amp;nbsp;±&amp;nbsp;20.3%,
 23.6&amp;nbsp;±&amp;nbsp;11%, and 31....</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5666797</comments>
            <pubDate>Fri, 03 Feb 2012 17:51:42 +0100</pubDate>
            <guid isPermaLink="false">5666797</guid>        </item>
        <item>
            <title>Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients</title>
            <link>http://www.medworm.com/index.php?rid=5666799&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv6146127l0h32730%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dendritic cells may be successfully used to induce in vivo-specific anti-tumor responses when combined with the appropriate
 antigen in the appropriate context. The purpose of this study was to evaluate efficacy of peptide-loaded DC vaccine in high-risk
 stage III melanoma patients after lymph node dissection (LND). HLA-A2+, -A1+, or -A3+ melanoma patients (N&amp;nbsp;=&amp;nbsp;22), stage III, N1b-N3, received 5–16 (median: 11) DC vaccines loaded with MHC class-I-restricted melanoma peptides respective
 to the patient’s haplotype, and with autologous tumor lysate, if available. Vaccinated patients were matched to unvaccinated
 stage III controls (22 of 869) by sex, number of metastatic lymph nodes, extracapsular involvement, LND type, Breslow stage,
 and ulceration. Vaccin...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5666799</comments>
            <pubDate>Thu, 02 Feb 2012 18:16:09 +0100</pubDate>
            <guid isPermaLink="false">5666799</guid>        </item>
        <item>
            <title>Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients</title>
            <link>http://www.medworm.com/index.php?rid=5666798&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd15177j211738vv7%2F</link>
            <description>This study aimed to investigate the relationship of LAPTM4B allelic variation and GBC susceptibility. LAPTM4B genotype was analyzed in 155 healthy individuals and 91 GBC patients by
 PCR, and the genotypic distribution of LAPTM4B was analyzed with the chi-squared test. The frequency of allele *2 was 37.9 and 24.8% in the GBC and the control groups,
 respectively, representing a significant difference between these two groups (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). LAPTM4B allele *2 may be a risk factor associated with genetic susceptibility to GBC.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-5DOI 10.1007/s12032-012-0173-4Authors
		Hua Yang, Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, 100191 ChinaGuojun Zhai, Department of Interventional R...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5666798</comments>
            <pubDate>Thu, 02 Feb 2012 18:16:09 +0100</pubDate>
            <guid isPermaLink="false">5666798</guid>        </item>
        <item>
            <title>Erratum to: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5659453&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp7012225j3654833%2F</link>
            <description>Content Type Journal ArticleCategory ErratumPages 1-1DOI 10.1007/s12032-012-0172-5Authors
		Tanja Badovinac-Črnjević, Oncology Department, University Hospital Zagreb, Kispaticeva 12, Zagreb, CroatiaGiulio Spagnoli, Institute of Research and Hospital Management, University of Basel, Basel, SwitzerlandAntonio Juretić, Oncology Department, University Hospital Zagreb, Kispaticeva 12, Zagreb, CroatiaJasminka Jakić-Razumović, Pathology Department, University Hospital Zagreb, Kispaticeva 12, Zagreb, CroatiaPaula Podolski, Oncology Department, University Hospital Zagreb, Kispaticeva 12, Zagreb, CroatiaNera Šarić, Oncology Department, University Hospital Zagreb, Kispaticeva 12, Zagreb, Croatia
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncolog...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659453</comments>
            <pubDate>Tue, 31 Jan 2012 07:11:08 +0100</pubDate>
            <guid isPermaLink="false">5659453</guid>        </item>
        <item>
            <title>Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=5659454&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx500683723202223%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hypoxia-induced factors (HIFs) play a central role in the adaptive mechanisms of cancer cells to survive under conditions
 of hypoxia. HIFs are regulated by prolyl hydroxylases (PHDs) among which PHD3 is implicated as a tumor suppressor. We aimed
 to correlate PHD3 expression with clinicopathologic parameters and to evaluate its prognostic significance in gastric cancer.
 The 101 tissue samples were collected from 83 resected stages I–IV gastric cancer patients, which were grouped as non-cancerous
 mucosa (n&amp;nbsp;=&amp;nbsp;18) and primary carcinoma (n&amp;nbsp;=&amp;nbsp;83). PHD3 expression was evaluated by immunohistochemistry. We adopted Pearson
 chi-square test, univariate analysis, multivariate analysis and Kaplan–Meier method. The positive frequency of PHD3 in cancer
 ce...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5659454</comments>
            <pubDate>Tue, 31 Jan 2012 07:11:07 +0100</pubDate>
            <guid isPermaLink="false">5659454</guid>        </item>
        <item>
            <title>S100B protein as a possible participant in the brain metastasis of NSCLC</title>
            <link>http://www.medworm.com/index.php?rid=5647201&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw61708060n603n22%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Brain metastasis is a frequent occurrence in lung cancer, especially non-small cell lung cancer (NSCLC), the prognosis for
 NSCLC with brain metastasis is very poor. Our previous study found high S100B expression in the brain-specific metastatic
 NSCLC line PC14/B, suggested S100B is closely correlated with brain metastasis in NSCLC. However, the details have not yet
 been revealed. The aim of this study was to investigate the correlation between S100B and brain metastasis in NSCLC and to
 study the effects of S100B on non-brain metastatic NSCLC line PC14. We investigated serum S100B levels in 30 newly diagnosed NSCLC patients (15 with brain metastasis and 15 without brain metastasis)
 using enzyme-linked immunosorbent assay. Results showed that serum S100B levels were ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647201</comments>
            <pubDate>Fri, 27 Jan 2012 17:56:11 +0100</pubDate>
            <guid isPermaLink="false">5647201</guid>        </item>
        <item>
            <title>Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia</title>
            <link>http://www.medworm.com/index.php?rid=5638198&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F541253100527270n%2F</link>
            <description>This study results indicates that especially PF β2&amp;nbsp;M and ferritin
 levels may be valuable for diagnosis of malignant ascites in patients with ovarian neoplasms.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-7DOI 10.1007/s12032-012-0165-4Authors
		Umran Kucukgoz Gulec, Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, Adana, TurkeySemra Paydas, Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, TurkeyAhmet Baris Guzel, Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, Adana, TurkeySelim Buyukkurt, Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, Adana, TurkeyGulsah Seydaoglu, Department of Biostatistics, Faculty of Medicine, Cukurova Unive...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638198</comments>
            <pubDate>Tue, 24 Jan 2012 18:13:18 +0100</pubDate>
            <guid isPermaLink="false">5638198</guid>        </item>
        <item>
            <title>High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638199&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl06047210746l242%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The laryngeal squamous cell carcinoma (LSCC) is one of the most common cancers threatening people’s life. CXC-chemokine receptor
 type 2 (CXCR2) was reported to play critical roles in angiogenesis, tumorigenesis, and metastasis of several cancers such
 as colon cancer, melanoma, lung cancer, and so on. However, the expression of CXCR2 in LSCC and its association with clinical
 characters of LSCC remain unclear. Quantitative real-time reverse transcription-PCR and immunohistochemistry were used, respectively,
 to analyze the mRNA level and protein level of CXCR2 in 109 cases of LSCC tissues and 28 cases of tumor-adjacent normal tissues.
 The expression of CXCR2 in LSCC was significantly higher than that in tumor-adjacent tissues. Moreover, the expression level
 of CXCR...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638199</comments>
            <pubDate>Tue, 24 Jan 2012 18:13:16 +0100</pubDate>
            <guid isPermaLink="false">5638199</guid>        </item>
        <item>
            <title>Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638200&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkl95t3p3u443170v%2F</link>
            <description>In this study,
 we investigate whether gene expression profiling of cervical cancer could be used to predict the prognosis of patient. A series
 of 100 primary cervical cancer patients who underwent radical hysterectomy between January 2001 and October 2006 were analyzed
 for gene expression profiles by using a custom oligonucleotide microarray containing probes for 1440 human tumor-related gene
 transcripts. Supervised analysis of gene expression data identified 19 genes that exhibited differential expression between
 cervical cancer and normal cervix. Then, all 100 patients were divided into the training (n&amp;nbsp;=&amp;nbsp;50) and testing sets (n&amp;nbsp;=&amp;nbsp;50). Using Cox regression and risk-score analysis, we identified a 7-gene (UBL3, FGF3, BMI1, PDGFRA, PTPRF, RFC4, and NOL7) signature f...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638200</comments>
            <pubDate>Tue, 24 Jan 2012 18:13:14 +0100</pubDate>
            <guid isPermaLink="false">5638200</guid>        </item>
        <item>
            <title>Different expression of CD146 in human normal and osteosarcoma cell lines</title>
            <link>http://www.medworm.com/index.php?rid=5638201&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx0q25vw734808l81%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The CD146 cell membrane adhesion molecule is highly expressed on the cell surface of several tumours. The level of its expression
 has been found to correlate directly with tumour progression and metastatic potential, thus establishing CD146 as an important
 candidate of tumour growth and metastasis. In order to characterize its expression in human osteosarcoma (OS) cell lines,
 we have examined the CD146 expression at protein and RNA levels in both normal and tumour osteoblast-like cell lines by several
 methods. Our results indicate that CD146 protein is expressed at low levels in normal osteoblast cells whereas it is highly
 expressed in all OS cell lines analysed, (SaOS, MG-63, U-2OS). Moreover, CD146 overexpression was partially reduced in shYY1
 cells, where the Y...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638201</comments>
            <pubDate>Tue, 24 Jan 2012 06:54:28 +0100</pubDate>
            <guid isPermaLink="false">5638201</guid>        </item>
        <item>
            <title>Single-nucleotide polymorphisms of integrins are associated with the risk and lymph node metastasis of oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638203&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6635033670104xu8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Integrins mediate cell-extracellular matrix (ECM) interaction and play a critical role in cell proliferation, migration, survival,
 and invasion. Polymorphisms of the Integrin gene can alter integrin protein expression, which may further increase the risk of malignancies or cause poor clinical outcomes.
 The aim of this study was to investigate the potential associations of single-nucleotide polymorphisms (SNPs) of the integrin gene with the susceptibility and clinicopathologic parameters of oral squamous cell carcinoma (OSCC). Two hundred patients
 with OSCC and 200 healthy volunteers were recruited. Five SNPs of Integrin genes were analyzed by polymerase chain reaction–restriction fragment length polymorphism genotyping. Their correlations
 with OSCC risk and clinic...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638203</comments>
            <pubDate>Tue, 24 Jan 2012 06:54:27 +0100</pubDate>
            <guid isPermaLink="false">5638203</guid>        </item>
        <item>
            <title>Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab</title>
            <link>http://www.medworm.com/index.php?rid=5638202&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Few5l852k28229833%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A 48-year-old man was referred to our hospital with the diagnosis of colon cancer with multiple hepatic metastases. After
 right hemicolectomy, the rapid progression of liver disease was treated with metronomic capecitabine and bevacizumab according
 to a study protocol. A gradual regression of metastatic lesions was observed during a 9-month treatment period. After conversion
 of liver disease to resectability, the histological examination disclosed the complete necrosis of all lesions, with the exception
 of small neoplastic foci inside a single nodule. The comparison of this type of histological findings with the classic sclero-hyaline
 pathological response, as well as its importance as indicator of response to antiangiogenic treatment, is discussed.
 
 
	Content Ty...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638202</comments>
            <pubDate>Tue, 24 Jan 2012 06:54:27 +0100</pubDate>
            <guid isPermaLink="false">5638202</guid>        </item>
        <item>
            <title>DNA repair gene variants in endometrial carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638204&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv52116715j281505%2F</link>
            <description>In this study, we investigated
 the association of the polymorphisms in the DNA repair genes, XRCC1 Arg399Gln, XRCC3 Thr241Met, XPD Lys751Gln, XPG Asp1104His,
 APE1 Asp148Glu, and HOGG1 Ser326Cys, with endometrium cancer risk. Two hundred and sixty-two women were included in the study.
 Endometrial biopsy was performed, and on the basis of diagnosis and histological examination, women were divided into two
 groups: a control group (n&amp;nbsp;=&amp;nbsp;158) and an endometrial cancer group (n&amp;nbsp;=&amp;nbsp;104). Genotypes were determined by PCR–RFLP assays in endometrial carcinoma patients and age-matched controls. In this
 study, we found that the frequencies of Glu+ and Asp/Glu genotypes in APE, Gln/Gln genotype of XRCC1, Met/Met genotype of
 XRCC3, Cys+ and Ser/Cys genotypes of HOGG1, His+ and ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638204</comments>
            <pubDate>Tue, 24 Jan 2012 06:54:26 +0100</pubDate>
            <guid isPermaLink="false">5638204</guid>        </item>
        <item>
            <title>Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis</title>
            <link>http://www.medworm.com/index.php?rid=5619772&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu677004788897441%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To study the role of SHP-1 methylation in the pathogenesis of myelodysplastic syndromes (MDS), we detect the methylation status
 of SHP-1 promoter and STAT3 phosphorylation of MDS patients by the methylation-specific PCR and Western blotting, respectively.
 It is found that the methylation rate of SHP-1 promoter of high-risk MDS patients (69.2%) was higher than that of the low-risk
 MDS patients (21.4%) (P&amp;nbsp;=&amp;nbsp;0.001). The expression rate of STAT3 phosphorylated protein of high-risk group was higher (66.7%), when compared with that
 of the low-risk group (18.2%) (P&amp;nbsp;=&amp;nbsp;0.0001). Correlation analysis showed that the methylation status of SHP-1 promoter is positive correlated with the expression
 of phosphorylated STAT3 in MDS patient (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5619772</comments>
            <pubDate>Thu, 19 Jan 2012 06:55:04 +0100</pubDate>
            <guid isPermaLink="false">5619772</guid>        </item>
        <item>
            <title>New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)</title>
            <link>http://www.medworm.com/index.php?rid=5619773&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj5576142549236q5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite recent advances in radiotherapy and chemotherapy, survival rates for squamous cell carcinoma of the head and neck
 (SCCHN) have remained poor. The focus of SCCHN therapy has more recently shifted to the molecular level, particularly the
 epidermal growth factor receptor (EGFR/ErbB) pathway. Several agents that target the EGFR pathway, including monoclonal antibodies
 and tyrosine kinase inhibitors, are under investigation for SCCHN. Searches of PubMed and results of key oncology congresses
 were performed to identify relevant articles and abstracts. The EGFR-targeted monoclonal antibody cetuximab is approved for
 the treatment of locally advanced SCCHN in combination with radiotherapy, for first-line treatment of recurrent or metastatic
 SCCHN in combination wit...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5619773</comments>
            <pubDate>Wed, 18 Jan 2012 07:00:09 +0100</pubDate>
            <guid isPermaLink="false">5619773</guid>        </item>
        <item>
            <title>Late temporal lobe necrosis after conventional radiotherapy for carcinoma of maxillary sinus</title>
            <link>http://www.medworm.com/index.php?rid=5597041&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flx821lp8045ph2g1%2F</link>
            <description>We report a case of cerebral radiation necrosis 5&amp;nbsp;years after radiotherapy
 for a maxillary sinus carcinoma.
 
 
	Content Type Journal ArticleCategory Review ArticlePages 1-3DOI 10.1007/s12032-011-0141-4Authors
		Madhava R. Kanakamedala, Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USAAli Mahta, Department of Neurosciences, Moores UCSD Cancer Center, University of California, 3855 Health Sciences Drive, San Diego, La Jolla, CA 92093-0819, USAJianlin Liu, Center for Stroke and Vascular Neurology, First Affiliated Hospital Medical College, Xi’an JiaoTong University, Xi’an, ChinaSantosh Kesari, Department of Neurosciences, Moores UCSD Cancer Center, University of California, 3855 Health Sciences Drive, San Diego, La Jolla, CA 92093-0819, US...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597041</comments>
            <pubDate>Sat, 14 Jan 2012 16:42:21 +0100</pubDate>
            <guid isPermaLink="false">5597041</guid>        </item>
        <item>
            <title>High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5597042&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7213780p72244078%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;VEGFR-1-mediated signaling promotes invasiveness by direct tumor activation in some cancers. However, VEGFR-1 expression and
 its relationship with clinical features and prognosis in HCC remained unclear. Overexpression of Snail is common in HCC and
 associated with poorer prognosis. Therefore, expression of VEGFR-1 and Snail was investigated in HCC cell lines and tissue
 specimens in our study, and special attention was paid to evaluating the role of VEGFR-1 expression in prognosis of HCC. Western
 blot and immunofluorescence were used to detect expression of VEGFR-1, Snail and MMP-9 in 4 HCC cell lines, respectively.
 Moreover, expression of these proteins was confirmed on the samples from 95 HCC patients who underwent curative resection
 using immunohistochemistry. R...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597042</comments>
            <pubDate>Sat, 14 Jan 2012 06:54:33 +0100</pubDate>
            <guid isPermaLink="false">5597042</guid>        </item>
        <item>
            <title>Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=5597044&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj4572p65m5v87656%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;CD133 has been identified as a putative cancer stem cell (CSC) marker in various cancers including colorectal cancer. The
 relation between CD133 expression and biological characteristics of colorectal cancer remains to be clarified. Protein expression
 of CD133 was immunohistochemically evaluated in surgical specimens of 225 patients with colorectal cancer who were treated
 by surgery, as well as those of 78 patients with rectal cancer who received preoperative chemoradiotherapy (CRT) followed
 by curative resection. The correlation between CD133 expression and clinicopathological features, tumor recurrence and overall
 survival was analyzed in both populations. Among 225 colorectal cancers without CRT, 93 (41.3%) were positive for CD133 expression,
 which was enhanced...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597044</comments>
            <pubDate>Fri, 13 Jan 2012 16:51:25 +0100</pubDate>
            <guid isPermaLink="false">5597044</guid>        </item>
        <item>
            <title>MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin</title>
            <link>http://www.medworm.com/index.php?rid=5597043&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb72218l771298223%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Survivin has been shown to be an ideal target for cancer gene therapy because of its strong antiapoptotic effect. MicroRNA-34a
 (miR-34a) can function as a tumor suppressor in some cancers through negative regulation of gene expression. However, the
 relationship between miR-34a and survivin in larynx squamous cell carcinoma (LSCC) has not been explored. The abundance of
 survivin mRNA and miR-34a in LSCC tissues were measured using quantitative real-time polymerase chain reaction. Their expression
 levels were analyzed and correlated with tumor differentiation, lymphatic metastasis, clinical stages, and survival rates.
 MiR-34a mimic was transfected using liposomes to increase its level in LSCC cancer cell line, Hep-2. The effects of miR-34a
 on survivin protein expres...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597043</comments>
            <pubDate>Fri, 13 Jan 2012 16:51:25 +0100</pubDate>
            <guid isPermaLink="false">5597043</guid>        </item>
        <item>
            <title>N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients</title>
            <link>http://www.medworm.com/index.php?rid=5597045&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr27k332h26u67424%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We investigated the role of N-acetyltransferases (NAT) in prostate cancer (PCa) susceptibility. NAT are polymorphic in the population and metabolize important carcinogenic
 products directly involved in the tumor initiation process. This prospective case–control study utilized the polymerase chain
 reaction-based restriction fragment length polymorphism method and comprised a cohort of consecutive 478 individuals: 126
 men with prostate cancer; 101 men with benign prostatic hyperplasia (BPH); and a control health population of 177 female and
 74 male blood donors from the same region. NAT2 slow or fast acetylators genotypes were determined by the combination of four variant alleles. Lifetime occupational history,
 dietary patterns, cigarette smoking and other anamnest...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597045</comments>
            <pubDate>Fri, 13 Jan 2012 16:51:24 +0100</pubDate>
            <guid isPermaLink="false">5597045</guid>        </item>
        <item>
            <title>Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution</title>
            <link>http://www.medworm.com/index.php?rid=5597046&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw7rk265jmg57k005%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Karyotype of myeloblasts at the time of AML diagnosis has been shown to be prognostic significant for pre-remission outcome
 and outcome after allo-SCT, but the latter requires further studies. We conducted a retrospective analysis of the impact of
 intermediate and unfavourable cytogenetics at the time of primary diagnosis on outcome after allo-SCT in de novo AML. The
 study included 169 patients who underwent allo-SCT at Karolinska University Hospital between 1980 and 2010. Intermediate and
 unfavourable cytogenetics were found in 129 (76%) and 40 patients (24%), respectively. Myeloablative and reduced-intensity
 conditioning were given to 120 (71%) and 49 (29%) patients, respectively. Allo-SCT was performed in CR1 in 122 patients (72%).
 TRM was 16% in both cytogenet...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597046</comments>
            <pubDate>Tue, 10 Jan 2012 16:49:53 +0100</pubDate>
            <guid isPermaLink="false">5597046</guid>        </item>
        <item>
            <title>A study of PKM2, PFK-1, and ANT1 expressions in cervical biopsy tissues in China</title>
            <link>http://www.medworm.com/index.php?rid=5581102&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1h2671h5637758v8%2F</link>
            <description>In conclusion, PKM2 and PFK-1 genes are associated closely with cervical carcinoma. The enhanced expressions of PKM2 and PFK-1
 indicate one developing signal of cervical carcinoma.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-7DOI 10.1007/s12032-011-0154-zAuthors
		Yang Yuan, School of Public Health, Central South University, Changsha, 410078 Hunan, ChinaPeng Guo-Qing, Department of O &amp; G, Xiangya Hospital Central-South University, Changsha, 410008 Hunan, ChinaTian Yan, Department of O &amp; G, Xiangya Hospital Central-South University, Changsha, 410008 Hunan, ChinaYing Hong-Lin, Department of O &amp; G, Xiangya Hospital Central-South University, Changsha, 410008 Hunan, ChinaHu Gong-Hua, School of Public Health, Central South University, Changsha, 410078 Hunan, ChinaZhong Cai-G...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5581102</comments>
            <pubDate>Sat, 07 Jan 2012 16:56:35 +0100</pubDate>
            <guid isPermaLink="false">5581102</guid>        </item>
        <item>
            <title>Is there association between handedness and radiosensitivity in breast cancer women?</title>
            <link>http://www.medworm.com/index.php?rid=5572003&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F555302116h328256%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Radiosensitivity is a biological response to radiation. This response depends on many factors such as radiation factors as
 well as biological system factors. It is shown that identical doses of radiation for the treatment of Cancer patients produce
 different biological responses that are assumed to be depend on different specifications of the biological systems. However,
 by elimination of these factors, people may still show different biological responses such as acute and low responses to radiotherapy
 in similar doses of radiation. Some reports indicate that breast cancer, immune diseases including autoimmune diseases such
 as lupus, Myasthenia Gravies and even the rate of allergy are more frequent in left-handed compared to right-handed individuals.
 The main goal...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572003</comments>
            <pubDate>Wed, 04 Jan 2012 17:03:03 +0100</pubDate>
            <guid isPermaLink="false">5572003</guid>        </item>
        <item>
            <title>Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis</title>
            <link>http://www.medworm.com/index.php?rid=5572005&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc3005l3888311585%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to identify novel serological tumor markers for human prostate cancer (PCa). We compared the gene
 expression profile of PCa tissues to adjacent benign tissues of prostate using gene expression microarray. 1207 genes that
 were consistently different from adjacent benign tissues of prostate (paired t test, P&amp;nbsp;&amp;lt;&amp;nbsp;0.05) were selected as differentially expressed genes (DEGs). Among them, 652 DEGs were upregulated in PCa, whereas 555
 DEGs were downregulated in PCa. In addition, two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) coupled
 with MS was performed to screen for candidate markers in the proteome of PCa and adjacent benign tissues of prostate. A total
 of 89 spots were significantly up-regulated (ratio&amp;nbsp;...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572005</comments>
            <pubDate>Wed, 04 Jan 2012 07:00:21 +0100</pubDate>
            <guid isPermaLink="false">5572005</guid>        </item>
        <item>
            <title>Human papillomavirus-16 (HPV-16) infection association with CIAP-2 expression in head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5572004&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl925k4rg90113192%2F</link>
            <description>In this study, we aimed to search for the amplification of the locus bearing CIAP-2 and its relation to HPV-16
 in head and neck cancer that may have prognostic and therapeutic impacts on these patients. Total 30 patients diagnosed as
 head and neck cancer (2 tissue samples were taken from each patient: from the tumor and from the safety margin). All samples
 were subjected to qualitative polymerase chain reaction analysis for HPV-16 and qualitative and semiquantitative reverse transcription
 polymerase chain reaction of CIAP-2. There was a significant association between HPV-16 and CIAP2 positivity and head and
 neck tumors (P&amp;nbsp;=&amp;nbsp;0.01). CIAP-2 expression in malignant tissues was highly associated with HPV-16 infection with 73.9% sensitivity and absolute
 specificity.
 
 
	Content...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5572004</comments>
            <pubDate>Wed, 04 Jan 2012 07:00:21 +0100</pubDate>
            <guid isPermaLink="false">5572004</guid>        </item>
        <item>
            <title>Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases</title>
            <link>http://www.medworm.com/index.php?rid=5559580&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl0317420wmr6h640%2F</link>
            <description>We present long-term disease treatment in a
 60-year-old woman having greater than thirty brain metastases of NSCLC adenocarcinoma with a mutant allele of EGFR treated
 with differing chemotherapies including erlotinib, but disease response in the brain only with bevacizumab. Although initially
 restricted in use, increasing clinical reports have demonstrated safety of bevacizumab use in brain-involved cancer patients.
 Our case highlights that disease response to bevacizumab is similar in the brain to systemic disease and likely overcomes
 anatomical barriers that can limit other therapeutic agents.
 
 
	Content Type Journal ArticleCategory Short CommunicationPages 1-4DOI 10.1007/s12032-011-0148-xAuthors
		Oana C. Danciu, Department of Medicine, Section of Hematology/Oncology, University ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5559580</comments>
            <pubDate>Fri, 30 Dec 2011 16:43:30 +0100</pubDate>
            <guid isPermaLink="false">5559580</guid>        </item>
        <item>
            <title>A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=5559582&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F38684q0048136153%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic myelogenous leukemia (CML) is a common myeloproliferative disease that is characterized by the clonal expansion of
 marrow stem cells, and is associated with the Philadelphia chromosome. As the disease progresses, additional chromosome abnormalities may arise. The prognostic impact of secondary
 chromosomal abnormalities in CML is complex, heterogeneous, and sometimes related to previous treatment. Here, we describe
 a CML patient in lymphoid blast crisis associated with a new chromosomal abnormality identified, dic(7;12)(p12.21;p12.2) and
 i(12)(q10) using classical cytogenetics and spectral karyotype analysis. To the best of our knowledge, this is the first report
 of t(7;12)(p11.1;q11.1) and i(12)(q10) in a CML patient with lymphoid evolution.
 
 
	Content Ty...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5559582</comments>
            <pubDate>Fri, 30 Dec 2011 16:43:29 +0100</pubDate>
            <guid isPermaLink="false">5559582</guid>        </item>
        <item>
            <title>Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia</title>
            <link>http://www.medworm.com/index.php?rid=5559581&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk885x154q7840730%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;MicroRNAs (miRNAs) are of great importance in pathogenesis, diagnosis and prognosis of acute leukemia (AL). We studied five
 AL-related miRNAs to confirm the significance of these miRNAs in AL. Samples tested included acute myeloid leukemia (AML),
 107 cases; acute lymphoblastic leukemia (ALL), 40 cases. Five AL-related miRNAs: miR-128, let-7b, miR-223, miR-181a and miR-155
 expression were detected by qRT-PCR. Analysis showed that miRNA-128 expression was significantly higher in ALL (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). However, the let-7b and miR-223 expressions in ALL were significantly lower than in AML (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). Compared with normal controls, miR-128 expression was significantly higher in ALL (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001), but there was no significant difference in ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5559581</comments>
            <pubDate>Fri, 30 Dec 2011 16:43:29 +0100</pubDate>
            <guid isPermaLink="false">5559581</guid>        </item>
        <item>
            <title>Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)</title>
            <link>http://www.medworm.com/index.php?rid=5559583&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr488l2746678532v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the
 second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined
 with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit. We investigated
 the efficacy of bevacizumab plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens without bevacizumab.
 Patients who received bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX as second-line chemotherapy between July 2007 and
 March 2008 were registered (trial registration: UMIN000001547). Patient background data and progression-free survival (PFS),
 overall survival (OS), respon...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5559583</comments>
            <pubDate>Fri, 30 Dec 2011 16:43:26 +0100</pubDate>
            <guid isPermaLink="false">5559583</guid>        </item>
        <item>
            <title>Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients</title>
            <link>http://www.medworm.com/index.php?rid=5559584&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F11pjl4171x58888n%2F</link>
            <description>In this study, we aimed to investigate the relationship between LAPTM4B allelic variation and HCC susceptibility. The LAPTM4B genotype was analyzed in the blood samples from 102 HCC patients and
 135 healthy individuals by PCR. The genotypic distribution of LAPTM4B was analyzed using the chi-squared test. The frequencies of allele *2 were 38.24 and 24.07% in the HCC group and control
 group, respectively, representing a significant difference between these two groups (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). Thus, allele *2 of LAPTM4B appears to be associated with genetic susceptibility of HCC and may therefore be considered as a risk factor.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-6DOI 10.1007/s12032-011-0139-yAuthors
		Guojun Zhai, Department of Interventional Radiology and Vascu...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5559584</comments>
            <pubDate>Fri, 30 Dec 2011 07:09:17 +0100</pubDate>
            <guid isPermaLink="false">5559584</guid>        </item>
        <item>
            <title>Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: two additional cases with clinical and laboratorial peculiar presentations</title>
            <link>http://www.medworm.com/index.php?rid=5552148&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgn8m2g18824j13r8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) and PML-RARa rearrangement, with good
 response to treatment with retinoids. However, few cases of variant APL involving alternative chromosomal aberrations have
 been reported, including t(11;17)(q23;q21) (Wells et al. in Nat Genet 17:109–113, 1; Arnould et al. in Hum Mol Genet 8:1741–1749, 2) t(5;17)(q35;q12-21), t(11;17)(q13;q21) (Grimwade et al in Blood 96:1297–1308, 3) and der(17) (Rego et al. in Blood (ASH Annual Meeting Abstracts)114:Abstract 6, 4), whereby RARa is fused to the PLZF, NPM, NuMA, and STAT5b genes, respectively, have been described. These cases are characterized
 by distinct morphology, clinical presentation, and in respect to PLZF, a lack of differentiation re...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5552148</comments>
            <pubDate>Wed, 28 Dec 2011 16:44:11 +0100</pubDate>
            <guid isPermaLink="false">5552148</guid>        </item>
        <item>
            <title>Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report</title>
            <link>http://www.medworm.com/index.php?rid=5552149&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa518451518005876%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This case report focuses on an elderly gentleman with extensive stage small cell lung cancer (SCLC) who experienced episodes
 of bowel obstruction shortly after commencing first-line chemotherapy with cisplatin and etoposide. The patient had no radiological
 or pathological evidence of intra-abdominal carcinomatosis or paraneoplastic bowel disease secondary to SCLC. Although neurotoxicity
 is commonly associated with platinum agents, the effect is predominantly peripheral as opposed to autonomic. The authors conclude
 that the observations documented in this case were secondary to etoposide; a podophyllotoxin that can bind microtubules and
 inhibit fast axonal transport. Although paralytic ileus is well recognised with podophyllotoxin poisoning, to our knowledge,
 this ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5552149</comments>
            <pubDate>Tue, 27 Dec 2011 17:01:56 +0100</pubDate>
            <guid isPermaLink="false">5552149</guid>        </item>
        <item>
            <title>Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?</title>
            <link>http://www.medworm.com/index.php?rid=5552150&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr72322321rh09215%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorPages 1-3DOI 10.1007/s12032-011-0146-zAuthors
		Julio Cesar Salas-Alanis, Department of Dermatology, Facultad de Medicina y Hospital Universitario Dr. José E. González, Universidad Autonoma de Nuevo Leon, Avenida Gonzalitos No. 235 Norte, Colonia Mitras Centro, CP64460 Monterrey, Nuevo León, MexicoRoger Gonzalez, Department of Dermatology, OnDerm. Centro de Dermatología, Dermatoscopía y Oncología Cutánea, Av. Loma Grande 2717-M6, Col. Lomas de San Francisco, Monterrey, Nuevo León, MexicoGiulio Fortuna, Program in Epithelial Biology, Department of Dermatology, Stanford University School of Medicine, 269 Campus Dr., Stanford, CA 94305, USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medic...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5552150</comments>
            <pubDate>Tue, 27 Dec 2011 17:01:55 +0100</pubDate>
            <guid isPermaLink="false">5552150</guid>        </item>
        <item>
            <title>The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis</title>
            <link>http://www.medworm.com/index.php?rid=5552151&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F640u635485244595%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to perform an immunohistochemical analysis from 100 megakaryocytes per sample, analyzing positivity
 and intensity levels of anti-LAP human TGF-β1 (or Latent TGF-β1) and anti-TGF-β1 (or Active TGF-β1) antibodies from 18 essential
 thrombocythemia (ET) and 38 primary myelofibrosis (PMF) patients (being 19 pre-fibrotic and 19 fibrotic). Six bone marrow
 donor biopsies were used as controls. Fibrosis in bone marrow biopsies (BMB) was evaluated according to the European Consensus.
 The average fibrosis grade differed between each group (P&amp;nbsp;=&amp;nbsp;0.001 or P&amp;nbsp;=&amp;nbsp;0.003). Latent TGF-β1 values differed significantly between pre-fibrotic (P&amp;nbsp;= 0.018) and fibrotic (P&amp;nbsp;=&amp;nbsp;0.031) groups when compared with the control group. The...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5552151</comments>
            <pubDate>Mon, 26 Dec 2011 16:45:23 +0100</pubDate>
            <guid isPermaLink="false">5552151</guid>        </item>
        <item>
            <title>Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification</title>
            <link>http://www.medworm.com/index.php?rid=5552152&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc17g98461151g1v5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We aimed to compare the survival benefit of transarterial chemoembolization (TACE) with conservative treatment for patients
 with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), furthermore, to reveal which PVTT types
 benefit from TACE treatment. From August 2007 to January 2010, a prospective controlled study was performed on consecutive
 patients with advanced HCC and PVTT. Of a total of 150 patients, 115 were treated with TACE (lipiodol and anticancer agents
 ± gelatin sponge embolization), and 35 who refused to accept the procedure were treated with conservative treatment. We performed
 survival analysis of the two treatment groups and then stratified by a new classification of PVTT that was divided into four
 types. Overall survival...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5552152</comments>
            <pubDate>Mon, 26 Dec 2011 16:45:22 +0100</pubDate>
            <guid isPermaLink="false">5552152</guid>        </item>
        <item>
            <title>Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells</title>
            <link>http://www.medworm.com/index.php?rid=5544267&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm121768481p89h12%2F</link>
            <description>In this study, the in vitro cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity
 (CDC) activities of anti-Sp17 mAb were evaluated using Sp17-positive ovarian cancer cells as targets, Sp17-negative ovarian
 cancer cells as the control, and healthy human peripheral blood monocytes and healthy human serum as effectors. Our preliminary
 results indicate that the direct cytotoxicity of anti-Sp17 mAb against the investigated ovarian cancer cells was very weak.
 However, the cytotoxicity of anti-Sp17 mAb, mediated by peripheral blood mononuclear cells (PBMCs), as ADCC, or by human serum,
 as CDC, was relatively strong in the Sp17-positive ovarian cancer cells. This finding suggested that anti-Sp17 mAb could be
 a useful tool against ovarian can...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5544267</comments>
            <pubDate>Fri, 23 Dec 2011 16:54:29 +0100</pubDate>
            <guid isPermaLink="false">5544267</guid>        </item>
        <item>
            <title>High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=5544266&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F68882k7pr2786l14%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Diffuse large B-cell lymphoma (DLBCL) is characterized by its clinical and biological heterogeneity. Although the International
 Prognostic Index (IPI) provides a clinical model for risk stratification of patients with DLBCL, notable variability in outcome
 is still observed within the same IPI category. Tumor-infiltrating macrophages (also called Tumor-associated macrophages)
 are the major component in the microenvironment of DLBCL. Their correlation with the prognosis of DLBCL remains controversial.
 Using a CD68 antibody in immunohistochemical analysis, we studied the expression of CD68 in 112 Chinese patients with DLBCL,
 with 65 patients (58%) categorized as low CD68 expression and 47 patients (42%) as high CD68 expression. The complete response
 (CR) rate of pati...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5544266</comments>
            <pubDate>Fri, 23 Dec 2011 16:54:29 +0100</pubDate>
            <guid isPermaLink="false">5544266</guid>        </item>
        <item>
            <title>Overexpression of EphA2 correlates with epithelial–mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients</title>
            <link>http://www.medworm.com/index.php?rid=5544268&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff674257015035661%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The expression of EphA2 and three epithelial–mesenchymal transition-related proteins (E-cadherin, β-catenin and vimentin)
 was detected by immunohistochemistry in human gastric cancer and normal gastric mucosa. The expression of EphA2 and vimentin
 was significantly higher in gastric cancer tissues than in normal gastric mucosa tissues, and similar results were found for
 negative E-cadherin expression and ectopic β-catenin expression. Further analysis showed that the expression of EphA2 was
 closely correlated with the depth of tumor invasion, tumor–node–metastasis (TNM) stages and lymph node metastasis. Down-regulated
 expression of the epithelial protein E-cadherin, overexpression of the mesenchymal protein vimentin and ectopic expression
 of β-catenin were ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5544268</comments>
            <pubDate>Wed, 21 Dec 2011 20:08:56 +0100</pubDate>
            <guid isPermaLink="false">5544268</guid>        </item>
        <item>
            <title>The -938A/A genotype of BCL2 gene is associated with esophageal cancer</title>
            <link>http://www.medworm.com/index.php?rid=5537493&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm40x504t283q516m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Perturbations in the apoptotic genes have been implicated in human malignancies. The purpose of the present study was to investigate
 the polymorphisms of -938C/A, Thr43Ala in anti-apoptotic B-cell lymphoma 2 gene (BCL2) and -248G/A in pro-apoptotic B-cell
 lymphoma 2-associated X protein gene (BAX) and to explore their role in influencing the susceptibility for development of
 esophageal cancer. A total of 205 esophageal cancer patients and 224 controls were enrolled in the present study. The genotype
 and allele distributions of -938C/A, ala43thr in BCL2 and -248G/A in BAX were analyzed in patients and controls, as well as
 the association of -938C/A genotype with clinical characteristics in patients. We found that homozygous -938A/A genotype of
 BCL2 gene was signifi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5537493</comments>
            <pubDate>Tue, 20 Dec 2011 16:48:34 +0100</pubDate>
            <guid isPermaLink="false">5537493</guid>        </item>
        <item>
            <title>Cells derived from normal or cancer breast tissue exhibit different growth properties when deprived of arginine</title>
            <link>http://www.medworm.com/index.php?rid=5524223&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx84761145278k484%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Arginine deprivation impairs cell proliferation more strong in cancer than in normal cells; thus, it has been proposed that
 such an effect could be exploited for cancer therapy. We have compared the effect of arginine deprivation on normal and cancer
 cells, studying growth rate, morphology, and protein expression patterns in immortalized human MCF10a cells and in MCF7 cells.
 Arginine deprivation forces MCF10a cells into irreversible senescence while the vast majority of MCF7 cells become quiescent
 and resume normal growth following arginine re-addition. Arginine deprivation induced a significant burst of p21cip1 in both cell lines that were reversible in MCF7 and irreversible in MCF10 cells. In the latter cells, p21cip1 increase was accompanied by a time-dependent i...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5524223</comments>
            <pubDate>Mon, 19 Dec 2011 16:54:13 +0100</pubDate>
            <guid isPermaLink="false">5524223</guid>        </item>
        <item>
            <title>Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study</title>
            <link>http://www.medworm.com/index.php?rid=5515175&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8464063552215272%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to evaluate the prognostic significance of international prognostic index (IPI), mantle cell lymphoma
 IPI (MIPI), simplified MIPI (sMIPI), and MIPI biological (MIPIb), as well as their correlation with immunophenotype, clinical
 characteristics, and overall survival (OS), in a selected group of 54 patients with advanced-stage mantle cell lymphoma (MCL),
 treated uniformly with CHOP. Seventeen patients had IV clinical stage (CS), while other 37 had leukemic phase at presentation.
 Diffuse type of marrow infiltration was verified in 68.5% and nodular in remainder patients. Extranodal localization (25.9%)
 included bowel (20.4%), pleural effusion, sinus, and palpebral infiltration. All of analyzed patients expressed typical MCL
 immunophenotypic ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5515175</comments>
            <pubDate>Wed, 14 Dec 2011 16:43:11 +0100</pubDate>
            <guid isPermaLink="false">5515175</guid>        </item>
        <item>
            <title>MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=5515176&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp464880318600757%2F</link>
            <description>In this study, we demonstrated that gastric cancer tissues and cell
 lines displayed a consistent down-regulation of miR-148a and hypermethylation of promoter region. DNMT1 was over-expressed
 in primary tumors and cell lines, while knockdown of DNMT1 using siRNA could decrease methylation level of miR-148a promoter
 and restore its expression. Furthermore, ectopic over-expression of miR-148a in cancer cell lines caused reduction in DNMT1
 expression and inhibited cell proliferation, but no obvious change was found in apoptosis rate. These results suggest that
 miR-148a is inactivated by DNA hypermethylation of promoter region in gastric cancer, which is mediated through DNMT1 over-expression.
 Additionally, the silence of miR-148a reduces its suppression to DNMT1 in gastric cancer, and th...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5515176</comments>
            <pubDate>Tue, 13 Dec 2011 17:03:38 +0100</pubDate>
            <guid isPermaLink="false">5515176</guid>        </item>
        <item>
            <title>Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5515177&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn4811q267r772437%2F</link>
            <description>In conclusion, reduced IGFBP-3 expression may be a risk factor for advanced clinicopathological classification
 and poor patient survival. These findings suggest that IGFBP-3 may serve as a useful marker for the prognostic evaluation
 of ESCC patients.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-8DOI 10.1007/s12032-011-0133-4Authors
		Lei Zhao, Department of Radiotherapy, Cancer Center, Sun Yat-Sen University, Guangzhou, No 651, Dongfeng road east, Guangzhou, 510060 ChinaLi-Ru He, Department of Radiotherapy, Cancer Center, Sun Yat-Sen University, Guangzhou, No 651, Dongfeng road east, Guangzhou, 510060 ChinaRui Zhang, Department of Radiotherapy, Cancer Center, Sun Yat-Sen University, Guangzhou, No 651, Dongfeng road east, Guangzhou, 510060 ChinaMu-Yan Cai, State Key Lab...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5515177</comments>
            <pubDate>Tue, 13 Dec 2011 17:03:37 +0100</pubDate>
            <guid isPermaLink="false">5515177</guid>        </item>
        <item>
            <title>Progranulin overexpression predicts overall survival in patients with glioblastoma</title>
            <link>http://www.medworm.com/index.php?rid=5504417&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh5n2m85m86120520%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite multimodal treatment, patients with astrocytoma still face a poor survival, and identification of valuable prognostic
 factors is crucial to yield effective individual therapy strategies. The aim of this study was to investigate progranulin
 (PGRN) expression in astrocytomas and explore its association with tumor grade and overall patient survival by scoring the
 PGRN immunoreactivity of both tumor cells and blood vessels. About 210 astrocytoma samples with different WHO grades and 14
 normal brain tissues were studied by immunohistochemistry for PGRN. Semi-quantitative RT-PCR and Western blot were carried
 out to confirm its expression in 35 tumor specimens. Serum levels of PGRN in glioblastoma were examined by enzyme immunometric
 assay. PGRN expression was al...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5504417</comments>
            <pubDate>Mon, 12 Dec 2011 17:17:09 +0100</pubDate>
            <guid isPermaLink="false">5504417</guid>        </item>
        <item>
            <title>Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia</title>
            <link>http://www.medworm.com/index.php?rid=5494707&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe81k45m146285563%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Imatinib is a powerful protein tyrosine kinase (PTK) inhibitor that specifically targets BCR-ABL, KIT, and PDGFR kinases,
 has become the current first-line therapy for all newly diagnosed chronic myeloid leukemia (CML). Beside PTKs, PTK inhibitors
 alter the activity of a large number of voltage-dependent ion channels. hERG1 K+ channels are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. The present
 study explored a possible regulatory effect of imatinib upon hERG1 K+ channels as a means to uncover new molecular events involved in the antileukemic activity of this PTK inhibitor in CML. The
 results demonstrated that hERG1 was highly detected in K562 cells and primary CML cells, and down-regulated by imatinib at
 mRNA...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5494707</comments>
            <pubDate>Fri, 09 Dec 2011 17:08:35 +0100</pubDate>
            <guid isPermaLink="false">5494707</guid>        </item>
        <item>
            <title>Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5486497&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F18w81135x346893t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There is an intimate relation between disturbance in survivin and SMAC/DIABLO expressions and cancer formation in many tissues;
 however, this was not confirmed in the primary breast cancer. The aim of this study was to evaluate the relationship between
 survivin and SMAC/DIABLO mRNA expressions in primary breast cancer using RT-PCR and their relationship to some of the risk
 factors (age, family history, breast-feeding, use of contraceptive pills and hormonal receptors). Breast cancer tissues were
 studied for the detection of the mRNA expression of survivin and SMAC/DIABLO. This was done by qualitative reverse transcription–polymerase
 chain reaction (RT-PCR). SMAC/DIABLO mRNA was detected by RT-PCR only in 1 sample in breast cancer tissues (6.25%). However,
 it was...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5486497</comments>
            <pubDate>Wed, 07 Dec 2011 16:44:39 +0100</pubDate>
            <guid isPermaLink="false">5486497</guid>        </item>
        <item>
            <title>Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab</title>
            <link>http://www.medworm.com/index.php?rid=5486496&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1n032r5553152606%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Corticosteroids are the mainstay of treatment of inflammatory pseudotumor (IPT) of the head and neck; however, involvement
 of the skull base and mandible can be unresponsive to steroids and require surgical resection. IPT is known to usually contain
 a CD20+ lymphocyte subgroup. Rituximab, a chimeric anti-CD20 antibody, has been successfully utilized in the treatment of
 other CD20+ diseases, including the similar idiopathic orbital inflammatory disease. This is the first report to describe
 successful treatment with Rituximab of a recurrent IPT of the mandible with trigeminal spread and leptomeningeal involvement
 with clinical and radiologic evidence demonstrating a sustained response to therapy.
 
 
	Content Type Journal ArticleCategory Case ReportPages 1-4DOI 10.10...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5486496</comments>
            <pubDate>Wed, 07 Dec 2011 16:44:39 +0100</pubDate>
            <guid isPermaLink="false">5486496</guid>        </item>
        <item>
            <title>Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5486498&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Femv410800h54j205%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Alcohol dehydrogenase 4 (ADH4) is an important member of ADH family that metabolize a wide variety of substrates including
 ethanol and retinol. Studies demonstrated that ADH4 was involved in cancer. Microarray data showed that the expression of
 ADH4 was reduced in hepatocellular carcinoma (HCC). However, the role of ADH4 in HCC carcinogenesis remains undefined. The
 aim of this study is to explore the clinical significance of ADH4 in progression and prognosis of HCC. The expression levels
 of ADH4 in 15 paired HCC and noncancerous (NC) liver tissues were measured by qRT-PCR and those in 4 paired samples by Western
 blotting. Another 91 paraffin-embedded HCC tissues were examined by immunohistochemistry. The qRT-PCR result showed that the
 expression level of ADH4 mRNA...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5486498</comments>
            <pubDate>Tue, 06 Dec 2011 17:00:45 +0100</pubDate>
            <guid isPermaLink="false">5486498</guid>        </item>
        <item>
            <title>Prognostic value of ADAM17 in human gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=5476242&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fyk98u18t65134g5k%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A disintegrin and metalloproteinase-17 (ADAM17, also named as tumor necrosis factor-alpha-converting enzyme) is a member of
 the ADAM family. Of all ADAMs, the strongest evidence for a role in malignancy exists for ADAM17. Especially, it has been
 demonstrated that ADAM17 expression was significantly increased in human gastric cancer. The aim of this study was to investigate
 the association between ADAM17 expression and the clinicopathological features of patients with gastric cancer. The expression
 of ADAM17 was detected by real-time quantitative RT-PCR in gastric cancer and adjacent non-cancerous tissues. In addition,
 ADAM17 expression was analyzed by immunohistochemistry in 220 clinicopathologically characterized gastric cancer cases. The
 expression levels of ADA...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5476242</comments>
            <pubDate>Fri, 02 Dec 2011 17:29:12 +0100</pubDate>
            <guid isPermaLink="false">5476242</guid>        </item>
        <item>
            <title>NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5476243&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F55v5427556564128%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent studies have demonstrated that N-Myc downstream-regulated gene 2 (NDRG2) may reduce the metastatic potential of breast
 cancer and hepatocellular carcinoma cells by regulating the expression of CD24, which is expressed in a large variety of solid
 tumors. The aim of this study was to clarify the clinical value of NDRG2 and CD24 expression in primary gallbladder carcinoma
 (GBC). One hundred and thirty GBC tissues were evaluated by immunohistochemistry for NDRG2 and CD24 expression. The associations
 of NDRG2 and CD24 expression with the clinicopathological characteristics and the overall survival of patients with GBC were
 analyzed. NDRG2 and CD24 were positively expressed in 49/130 (37.69%) and 107/130 (82.31%) of GBC tissues, respectively. In
 addition, the tum...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5476243</comments>
            <pubDate>Thu, 01 Dec 2011 19:22:11 +0100</pubDate>
            <guid isPermaLink="false">5476243</guid>        </item>
        <item>
            <title>Note from publisher</title>
            <link>http://www.medworm.com/index.php?rid=5468510&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd7255111021u8m53%2F</link>
            <description>Content Type Journal ArticleCategory PUBLISHER NOTEPages 1-1DOI 10.1007/s12032-011-0124-5

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5468510</comments>
            <pubDate>Wed, 30 Nov 2011 18:40:26 +0100</pubDate>
            <guid isPermaLink="false">5468510</guid>        </item>
        <item>
            <title>Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population</title>
            <link>http://www.medworm.com/index.php?rid=5449585&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkw7803u2v0457kh7%2F</link>
            <description>This study was designed to investigate the association of apoptosis-related
 gene Caspase 8, Caspase 9 and Bcl-2 polymorphisms with papillary thyroid carcinoma (PTC) susceptibility. We undertook a case–control study of 118 patients and
 213 controls to investigate the association between Caspase 8 (-652 6&amp;nbsp;N ins/del), Caspase 9 (-1263 A&amp;gt;G) and Bcl-2 (-938 C&amp;gt;A) polymorphisms and PTC susceptibility by polymerase chain reaction restriction–fragment length polymorphism and
 DNA sequencing methods. We further analyzed the distribution of genotype frequency, as well as the association of genotype
 with clinicopathological characteristics. Overall, no statistically significant association was observed in Caspase 8 (-652 6&amp;nbsp;N ins/del). Nevertheless, Caspase 9 -1263 GG genotype wa...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449585</comments>
            <pubDate>Fri, 25 Nov 2011 17:42:47 +0100</pubDate>
            <guid isPermaLink="false">5449585</guid>        </item>
        <item>
            <title>Primary pure signet-ring cell adenocarcinoma of the urinary bladder: a report of three cases with an immunohistochemical study</title>
            <link>http://www.medworm.com/index.php?rid=5449586&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj4466212104j775t%2F</link>
            <description>In conclusion, the author presents three cases of primary
 pure SRCA with an emphasis of immunohistochemical findings.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-4DOI 10.1007/s12032-011-0122-7Authors
		Tadashi Terada, Department of Pathology, Shizuoka City Shimizu Hospital, Miyakami 1231 Shimizu-Ku, Shizuoka, 424-8636 Japan
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449586</comments>
            <pubDate>Fri, 25 Nov 2011 17:42:46 +0100</pubDate>
            <guid isPermaLink="false">5449586</guid>        </item>
        <item>
            <title>Girdin protein: a new potential distant metastasis predictor of breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5449588&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F44mg8301007061n2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To investigate the expression status and the clinical implications of Girdin protein in breast cancer. The expression status
 of Girdin protein and clinicopathological parameters in 820 breast cancer specimens was analyzed using immunohistochemistry
 staining and the relationship between Girdin protein and clinicopathological parameters. The prognosis of breast cancer was
 subsequently determined. Girdin protein was expressed positively in 295 (35.98%) of the 820 cases examined. The expression
 of Girdin protein was related to histological type and CerbB2 (P&amp;nbsp;=&amp;nbsp;0.001, 0.006, and 0.001, respectively). After analyzing survival rates, the cases with highly expressed Girdin protein
 were shown to attain a significantly more distant metastasis rate and poorer postop...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449588</comments>
            <pubDate>Thu, 24 Nov 2011 17:53:27 +0100</pubDate>
            <guid isPermaLink="false">5449588</guid>        </item>
        <item>
            <title>High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5449587&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc163644p81975704%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent studies indicate that ER/PR/HER-2-negative (triple-negative, TN) breast cancers may be “CTA-rich” tumors, suggesting
 the possibility of CTA-based cancer vaccines as a treatment option for patients bearing these tumors. MAGE-A10 together with
 NY-ESO-1 is probably the most immunogenic CTA, representing a potentially highly attractive target of active specific immunotherapies.
 Paraffin-embedded tumor sections were collected retrospectively from 165 breast cancer patients diagnosed between 2002 and
 2003. Immunohistochemical staining for MAGE-A10 and NY-ESO-1 was performed. The expression of MAGE-A10 and NY-ESO-1 was correlated
 with other clinicopathological variables. MAGE-A10 expression (score&amp;nbsp;≥&amp;nbsp;2+) was detected in 105/164 (64%), and NY-ESO-1 ex...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449587</comments>
            <pubDate>Thu, 24 Nov 2011 17:53:27 +0100</pubDate>
            <guid isPermaLink="false">5449587</guid>        </item>
        <item>
            <title>Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML</title>
            <link>http://www.medworm.com/index.php?rid=5449589&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb3233k1384h533w0%2F</link>
            <description>In this study, array comparative genomic hybridization (aCGH) was used
 to distinguish eight cases of AML cases. Validation was performed by FISH and quantitative genomic PCR. The aCGH revealed
 new large and small recurrent genomic imbalances, such as gains of 1p36, 10q26, 11p15, 20q13, 22q23, harboring many proto-oncogenes.
 These results better define genetically the studied cases and could be used to understand the multiple phenomena involved
 in leukemogenesis.
 
 
	Content Type Journal ArticleCategory Short CommunicationPages 1-5DOI 10.1007/s12032-011-0108-5Authors
		Ana Rosa S. Costa, Division of Hematology and Hemotherapy, UNIFESP/Escola Paulista de Medicina, Rua Botucatu, 740, 3º andar, São Paulo, SP CEP: 04023-900, BrazilSintia I. Belangero, Division of Genetics, UNIFESP/Escola...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449589</comments>
            <pubDate>Thu, 24 Nov 2011 17:53:26 +0100</pubDate>
            <guid isPermaLink="false">5449589</guid>        </item>
        <item>
            <title>Polymorphism in pre-miR-30c contributes to gastric cancer risk in a Chinese population</title>
            <link>http://www.medworm.com/index.php?rid=5449590&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcr347k2mh76h8500%2F</link>
            <description>This study demonstrates that pre-miR-30c A/G polymorphism may be associated with an increased risk of gastric cancer in a Chinese population through altering mature
 miR-30c expression. However, their role as novel biomarkers for the diagnosis and prognosis of gastric diseases still needs
 to be systematically evaluated.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-10DOI 10.1007/s12032-011-0115-6Authors
		Yong-ping Mu, Department of Cell Biology, Capital Medical University, Beijing, 100069 ChinaXiu-lan Su, Department of Cell Biology, Capital Medical University, Beijing, 100069 China
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449590</comments>
            <pubDate>Tue, 22 Nov 2011 17:59:31 +0100</pubDate>
            <guid isPermaLink="false">5449590</guid>        </item>
        <item>
            <title>Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study</title>
            <link>http://www.medworm.com/index.php?rid=5449591&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F30t64r2318272366%2F</link>
            <description>This study sought
 to investigate recurrence patterns of GBM treated with temozolomide-based chemoradiation. Records for 31 patients treated
 for newly diagnosed GBM between 2007 and 2009 were retrospectively analyzed. Ten patients received maximal surgical resection
 followed by conventionally fractionated radiation (CFR) to a median dose of 60&amp;nbsp;Gy with concurrent and planned adjuvant temozolomide.
 Twelve patients were treated with maximal surgical debulking, intracavitary brachytherapy (ICB), and external beam radiation
 therapy with concurrent and planned adjuvant temozolomide. The remaining 9 patients had unresectable disease and underwent
 biopsy followed by a hypofractionated course of radiation to a median dose of 60&amp;nbsp;Gy over 10 fractions. Tumor failure was classified
 as l...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5449591</comments>
            <pubDate>Tue, 22 Nov 2011 17:59:29 +0100</pubDate>
            <guid isPermaLink="false">5449591</guid>        </item>
        <item>
            <title>Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5440402&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F21qr512627m3n727%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dysadherin is a cancer-related cell membrane glycoprotein, recently identified, playing an important role in tumor progression
 and metastasis. In the present minireview article, we are focusing on the role of dysadherin in E-cadherin downregulation,
 the various expression patterns of the molecule in head and neck cancer as well as its potential role as a molecular target
 for future applications in diagnosis, clinical routine and prognosis of the disease.
 
 
	Content Type Journal ArticleCategory Review ArticlePages 1-5DOI 10.1007/s12032-011-0118-3Authors
		Alexandros Georgolios, Department of Otorhinolaryngology, Virginia Commonwealth University, Richmond, VA, USAAnna Eleftheriadou, Department of Otorhinolaryngology, General Hospital of Rethymnon, P.O. Box 269, 74100...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5440402</comments>
            <pubDate>Mon, 21 Nov 2011 18:09:23 +0100</pubDate>
            <guid isPermaLink="false">5440402</guid>        </item>
        <item>
            <title>Mechanisms of Apoptin-induced cell death</title>
            <link>http://www.medworm.com/index.php?rid=5440403&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0k352gm84jp00774%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Apoptin, a 13.6-kD protein encoded by chicken anemia virus, is paid more and more attention, since it selectively induces
 apoptosis in tumor cells while abolishes cytotoxic effect in normal cells. In addition, Apoptin shows different localization
 in tumor cells and normal cells: it predominantly accumulates in nucleus of tumor cells, whereas in normal cells, it is detected
 mainly in cytoplasm. There are various mechanisms implicated in the program of Apoptin-mediated cell death. Up to now, the
 interpretations have been recognized including that the particular domains control nucleocytoplasmic shuttling of Apoptin,
 phosphorylation on specific residue and varies relevant signaling contribute to Apoptin’s activity, and the partners interacted
 with Apoptin regulate ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5440403</comments>
            <pubDate>Mon, 21 Nov 2011 18:09:21 +0100</pubDate>
            <guid isPermaLink="false">5440403</guid>        </item>
        <item>
            <title>Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women</title>
            <link>http://www.medworm.com/index.php?rid=5440404&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp046757562542760%2F</link>
            <description>This study acted to determine the methylation
 status of the ERβ promoter and its correlation with clinicopathological features of sporadic breast cancers in Chinese women, and lay a foundation
 for the management of breast cancer. In total, 178 cases with sporadic breast cancers were enrolled in the study. ERβ methylation was determined using a methylation-specific polymerase chain reaction (MSP). In general, ERβ promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia
 (44.9% vs. 14.3%, X
 2&amp;nbsp;=&amp;nbsp;4.986, P&amp;nbsp;=&amp;nbsp;0.026). A total of 58% (40/69) of ERβ-negative tumors got methylation compared with 36.7% (40/109) of ERβ-positive cases
 being methylated (X
 2&amp;nbsp;=&amp;nbsp;7.728, P&amp;nbsp;=&amp;nbsp;0.005). The ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5440404</comments>
            <pubDate>Mon, 21 Nov 2011 18:09:20 +0100</pubDate>
            <guid isPermaLink="false">5440404</guid>        </item>
        <item>
            <title>GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility</title>
            <link>http://www.medworm.com/index.php?rid=5431432&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq3357v4212438204%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The significance of translation regulatory factors in elevating the risk of cancer has been recently recognized. Eukaryotic
 release factor 3a (eRF3a) is a translation termination protein that is encoded by G1 to S phase transition 1 gene (GSPT1). The eRF3a/GSPT1 exon 1 contains a trinucleotide GGC repeat coding for a polyglycine expansion in the N-terminal of the protein. In the present
 study, we determined the allelic length of the GGCn repeat in the eRF3a gene in 250 women with breast cancer and 250 age-matched controls. Our results show that the presence of the longer allele,
 12-GGC, is correlated with threefold increased risk of breast cancer development. Our findings also suggest that women who
 are homozygous for 7-GGC allele are possibly at higher risk of deve...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5431432</comments>
            <pubDate>Fri, 18 Nov 2011 17:30:22 +0100</pubDate>
            <guid isPermaLink="false">5431432</guid>        </item>
        <item>
            <title>Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI</title>
            <link>http://www.medworm.com/index.php?rid=5431433&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F068h46v877825q56%2F</link>
            <description>In conclusion, the results showed the silibinin effectson reducing the rate of metastasis, migration and adhesion of MDA-MB-231
 to distant organs.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-7DOI 10.1007/s12032-011-0113-8Authors
		Mohadeseh Dastpeyman, Department of Molecular and Cellular Biology, University of Tehran, Tehran, IranNasrin Motamed, Department of Molecular and Cellular Biology, University of Tehran, Tehran, IranKayhan Azadmanesh, Department of Virology, Pasteur Institute of Iran, Tehran, IranEhsan Mostafavi, Department of Epidemiology, Pasteur Institute of Iran, Tehran, IranVahid Kia, Department of Virology, Pasteur Institute of Iran, Tehran, IranAli Jahanian-Najafabadi, Department of Molecular Biology, Pasteur Institute of Iran, Tehran, IranMohammad Ali ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5431433</comments>
            <pubDate>Fri, 18 Nov 2011 17:30:21 +0100</pubDate>
            <guid isPermaLink="false">5431433</guid>        </item>
        <item>
            <title>Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery</title>
            <link>http://www.medworm.com/index.php?rid=5431435&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff731326m83430454%2F</link>
            <description>This study investigated the expression pattern of vasohibin-1, its correlation with clinicopathological
 features, and its potential role in tumor angiogenesis and prognosis of HCC. Expression of vasohibin-1, vascular endothelial
 growth factor-A (VEGF-A), and intratumoral microvessel density (MVD, labeled by CD34) were assessed by immunohistochemistry
 in 117 HCC specimens and adjacent nontumor liver tissues (ANLT). Correlation between vasohibin-1 and VEGF-A, MVD, and clinicopathological
 features was then investigated. Prognostic value of these factors was determined using Kaplan–Meier analysis and a Cox proportional
 hazards regression model. Cytoplasm high expression of vasohibin-1 was detected in 38.5% (45/117) of the HCC tissues, which
 was significantly higher than that in 16.2% (...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5431435</comments>
            <pubDate>Fri, 18 Nov 2011 17:30:20 +0100</pubDate>
            <guid isPermaLink="false">5431435</guid>        </item>
        <item>
            <title>Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5431434&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp23661v866247864%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Drug resistance remains a major clinical obstacle to successful treatment in breast cancer patients, and the evidence of microRNAs
 involvement in cancer drug resistance has been emerging recently. However, the role of microRNA-200c (miR-200c) in modulating
 chemoresistance of breast cancer remains largely unexplored. Here, we investigated the miR-200c expression in tumor specimens
 obtained from thirty-nine breast cancer patients who received neoadjuvent chemotherapy by quantitative real-time PCR. Down-regulated
 miR-200c was observed in non-responders as compared to responders. In addition, miR-200c expression was observed to be down-regulated
 over 800-fold in human breast cancer cells resistant to doxorubicin MCF-7/ADR as compared to the parental MCF-7 cells. Up-reg...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5431434</comments>
            <pubDate>Fri, 18 Nov 2011 17:30:20 +0100</pubDate>
            <guid isPermaLink="false">5431434</guid>        </item>
        <item>
            <title>Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression</title>
            <link>http://www.medworm.com/index.php?rid=5421722&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0284822577626153%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To explore the clinical implication of activin receptor-like kinase 7 (ALK7) expression in breast cancer, we evaluated its
 protein level in six kinds of human breast tissue samples, including adjacent normal tissues, adenosis, breast fibroadenoma,
 ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and lymph node metastases (LNM). Immunohistochemical analyses
 showed that ALK7 was more frequently and much more intensely expressed in adjacent normal tissues, adenosis, and fibroadenoma
 tissues than in malignant tissues (DCIS, IDC, and LNM). Furthermore, the ALK7 expression in primary tumors and the corresponding
 LNM was evaluated in parallel samples from 60 patients with IDC. Results showed that the ALK7 expression status in primary
 tumors and LNM was c...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5421722</comments>
            <pubDate>Tue, 15 Nov 2011 16:50:00 +0100</pubDate>
            <guid isPermaLink="false">5421722</guid>        </item>
        <item>
            <title>Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment</title>
            <link>http://www.medworm.com/index.php?rid=5421724&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7k582u542635072n%2F</link>
            <description>This study demonstrated that the in vivo responses of malignant cells from CLL patients
 after administration of purine analogs (cladribine/fludarabine) with cyclophosphamide vary significantly. For comparative
 purposes, the sensitivity of leukemic cells obtained from the same CLL patients to conventional purine analogs and the selective
 CDK inhibitor R-roscovitine (ROSC) was determined, with and without the addition of an alkylating agent, prior to the onset of in vivo therapy.
 The kinetics and rate of spontaneous and drug-induced apoptosis of CLL cells under ex vivo conditions differed significantly
 between patients, mirroring the variability observed during in vivo treatment. Interestingly, individual patients’ leukemic
 cells were comparably sensitive to the drugs under both cond...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5421724</comments>
            <pubDate>Tue, 15 Nov 2011 16:49:59 +0100</pubDate>
            <guid isPermaLink="false">5421724</guid>        </item>
        <item>
            <title>Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5421723&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff86501362h742w24%2F</link>
            <description>This report
 is the first to investigate the expression and clinical significance of pRON in human ESCC. Quantitative polymerase chain
 reaction revealed an up-regulation of RON mRNA in 70% (7/10) of ESCC tissues when compared to the adjacent nontumor tissues.
 An overexpression of pRON protein was found in most of the ESCC cell lines studied (4/5) when compared to two non-neoplastic
 esophageal epithelial cells using immunoblot. In 64 ESCC tissues, pRON was localized at the cell membrane, cytoplasm and nucleus
 in 15 (23.4%), 63 (98.4%) and 61 (95.3%) cases using immunohistochemistry. Patients having high expression of cytoplasmic
 pRON significantly associated with shorter median survival when compared to those with low expression (25.41&amp;nbsp;months vs. 14.43&amp;nbsp;months),
 suggesting cy...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5421723</comments>
            <pubDate>Tue, 15 Nov 2011 16:49:59 +0100</pubDate>
            <guid isPermaLink="false">5421723</guid>        </item>
        <item>
            <title>Type 2 diabetes mellitus and prognosis in early stage breast cancer women</title>
            <link>http://www.medworm.com/index.php?rid=5421725&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn040u14k14n02r20%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;It has been suggested that type 2 diabetes mellitus may affect breast cancer prognosis, possibly due to increased diabetes-related
 comorbidity, or direct effects of insulin resistance and/or hyperinsulinemia. The aim of this study was to determine the impact
 of diabetes on disease-free survival (DFS) following mastectomy for breast cancer patients. The cases included in this retrospective
 study were selected from breast cancer women who had undergone mastectomy and completed adjuvant chemotherapy from 1998 to
 2010. Patients were classified into two groups: diabetic and non-diabetic. Patients’ age, sex, menopausal status, body mass
 index (BMI), histopathological features, tumor size, lymph node involvement, hormone receptor and HER2-neu status, and treatment
 type...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5421725</comments>
            <pubDate>Mon, 14 Nov 2011 16:54:33 +0100</pubDate>
            <guid isPermaLink="false">5421725</guid>        </item>
        <item>
            <title>Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of</title>
            <link>http://www.medworm.com/index.php?rid=5407334&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb3tn107123t01167%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA).
 Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin (Hb)
 levels &amp;lt;10&amp;nbsp;g/dL (US) or ≤10&amp;nbsp;g/dL (EU). The present exploratory analysis of a DA trial examined how baseline-Hb levels at ESA
 initiation affect transfusion rates, Hb response, and safety outcomes in CIA patients. Data were retrospectively analyzed
 from a phase 3 trial of CIA patients randomised to 500&amp;nbsp;mcg DA every 3&amp;nbsp;weeks (Q3&amp;nbsp;W) or to 2.25&amp;nbsp;mcg/kg DA weekly (QW) for 15&amp;nbsp;weeks.
 In the current analysis, data were reanalyzed by baseline-Hb categories of &amp;lt;9&amp;nbsp;g/dL (n&amp;nbsp;=&amp;nbsp;12...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407334</comments>
            <pubDate>Sat, 12 Nov 2011 16:54:39 +0100</pubDate>
            <guid isPermaLink="false">5407334</guid>        </item>
        <item>
            <title>Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=5407335&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F467w626443011q34%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute
 myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis,
 cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic
 AML and a follow-up of 36&amp;nbsp;months. The median patient age was 58&amp;nbsp;years, with a range of 18–79. CD56+ antigen was recorded in
 40 patients (21.7%). CD56&amp;nbsp;+&amp;nbsp;was the most significant risk factor for OS: P&amp;nbsp;=&amp;nbsp;0.05. The most significant factor for a poor rate of CR was age&amp;nbsp;≥&amp;nbsp;55&amp;nbsp;years (P&amp;nbsp;=&amp;nbsp;0.001). CD56 positivity had no significant influence ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407335</comments>
            <pubDate>Fri, 11 Nov 2011 16:45:28 +0100</pubDate>
            <guid isPermaLink="false">5407335</guid>        </item>
        <item>
            <title>Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese</title>
            <link>http://www.medworm.com/index.php?rid=5407336&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F26q7881165m3m525%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The development of breast cancer is a multistep process associated with complex changes in host gene expression patterns including
 inactivation of tumor suppressor genes and activation of oncogenes. Critically, hereditary predisposition plays a significant
 role in cancer susceptibility. However, mutation of the BRCA1 gene is found only in the minority of hereditary breast cancer, which indicates that there might be alternative, novel mechanisms
 contributing to inactivation of the BRCA1 gene. Studies have shown that aberrant methylation of genomic DNA plays an important role in carcinogenesis. The aim of this
 study was to investigate whether DNA methylation may be an alternative mechanism for the inactivation of BRCA1 as an epigenetic modification of the genome and w...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407336</comments>
            <pubDate>Thu, 10 Nov 2011 16:54:47 +0100</pubDate>
            <guid isPermaLink="false">5407336</guid>        </item>
        <item>
            <title>Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=5407339&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F432151v5147gv041%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Breast cancer is the most common type of cancer among women worldwide, and the incidence of breast cancer is increasing in
 the developing world. Estrogen exposure is a major risk factor for breast cancer, and estrogen oxidative metabolites have
 been implicated in chemical carcinogenesis. Xeroderma pigmentosum complementary group C (XPC) plays an important and multifaceted
 role in cell protection from oxidative DNA damage. Thus, XPC inactivation may be involved in the early stage of breast cancer.
 The aim of this study was to investigate the expression of XPC protein in sporadic breast cancer tissues and determine whether
 XPC expression influences breast cancer malignancy and clinical outcome. Fifteen cases of adjacent non-tumor breast tissue,
 28 cases of fibroaden...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407339</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:53 +0100</pubDate>
            <guid isPermaLink="false">5407339</guid>        </item>
        <item>
            <title>The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience</title>
            <link>http://www.medworm.com/index.php?rid=5407338&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc75p7u477t2n6r25%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of the study was to evaluate event-free survival (EFS), overall survival (OS) and safety for early addition of
 arsenic trioxide (As2O3) as frontline consolidation therapy compared to high-dose arabinoside (HiDAC) in adult patients with de novo acute promyelocytic
 leukemia (APL). 271 patients (aged 17–65&amp;nbsp;years) received consolidation therapy containing As2O3 (two 21-day courses) or HiDAC regimen. EFS at 5&amp;nbsp;years was 75% versus 54% (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001), and OS at 5&amp;nbsp;years was 83% versus 71% (P&amp;nbsp;=&amp;nbsp;0.002) in As2O3 and HiDAC treatment arms. 139 patients treated with As2O3, EFS at 5&amp;nbsp;years reached 79% versus 56% (P&amp;nbsp;=&amp;nbsp;0.014), but OS at 5&amp;nbsp;years was 77% versus 84% (P&amp;nbsp;=&amp;nbsp;0.32) in low-risk (WBC&amp;nbsp;≤&amp;nbsp;10&amp;...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407338</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:53 +0100</pubDate>
            <guid isPermaLink="false">5407338</guid>        </item>
        <item>
            <title>Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides</title>
            <link>http://www.medworm.com/index.php?rid=5407337&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl46541756708k663%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth
 regulatory proteins. In LNCaP cells, we evaluated both monospecific and bispecific oligos that targeted and comparably suppressed
 the expression of bcl-2, an apoptosis inhibitory protein. Cells compensated with both suppressed caspase-3 (an apoptosis promoter)
 activity, and an enhancement of both androgen receptor (AR) and p300 expression. This suggests that a progression to increased
 androgen sensitivity accompanies bcl-2 suppression, in this tumor line. To further evaluate mechanisms of adaptation, we now
 evaluate the effects upon the expression of insulin-like growth factor (IGF1) and another AR coactivator, IL-4, thought to
 increase prost...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407337</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:53 +0100</pubDate>
            <guid isPermaLink="false">5407337</guid>        </item>
        <item>
            <title>Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients</title>
            <link>http://www.medworm.com/index.php?rid=5407340&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F37242u56326240g6%2F</link>
            <description>The objectives of this study are to explore the clinical features and treatment outcomes and to investigate the correlation
 between microvessel density (MVD) and survival in patients with angioimmunoblastic T-cell lymphoma (AITL). We retrospectively
 analyzed clinical and follow-up data of 31 patients treated in two hospitals during 1995–2009 histologically proven AITL.
 We also assessed MVD in the lump of 31 previously untreated patients using α-CD34 immunohistochemical staining. The median
 age of the 31 patients was 48&amp;nbsp;years, eighty percent of the patients were in an advanced stage. 67.7% of them had B symptoms,
 with the follow-up of 2–13&amp;nbsp;years, the 5-year overall survival rate was 25.8%. The response rates (RR) of CHOP group and COP
 (cyclophosphamide, vincristine and ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407340</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:52 +0100</pubDate>
            <guid isPermaLink="false">5407340</guid>        </item>
        <item>
            <title>Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population</title>
            <link>http://www.medworm.com/index.php?rid=5407342&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj5855k8763531707%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The global physiological function of specifically expressed genes of prostate cancer in Chinese patients is unclear. This
 study aims to determine the genome-wide expression of genes related to prostate cancer in the Chinese population. Genes that
 were differentially expressed in prostate cancer were identified using DNA microarray technology. Expressions were validated
 by using real-time PCR. The identified genes were analyzed using the ingenuity pathway analysis (IPA) to investigate the gene
 ontology, functional pathway and network. A total of 1,444 genes (Fold time&amp;nbsp;≥&amp;nbsp;1.5; P&amp;nbsp;≤&amp;nbsp;0.05) were differentially expressed in prostate primary tumor tissue compared with benign tissue. IPA revealed a unique
 landscape where inductions of certain pathways...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407342</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:51 +0100</pubDate>
            <guid isPermaLink="false">5407342</guid>        </item>
        <item>
            <title>Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=5407341&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft78102j0372063w6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In chronic myeloid leukemia (CML), the best characterized imatinib resistance mechanisms are BCR-ABL tyrosine kinase domain
 mutations and clonal evolution, but recently alternative splicing of BCR-ABL was also proposed as a mechanism for imatinib
 resistance. Among recently reported BCR-ABL splice variants, exon 7 deletion (Δexon7) was characterized in this study. The
 frequency of Δexon7 was investigated in 30 healthy controls and in 76 CML patients at different time points of the disease
 course by four different molecular genetic methods (direct sequencing, fragment analysis, allele-specific and quantitative
 PCR). The functionality and viability of the variant protein was tested by bioinformatic prediction. The Δexon7 was abundantly
 detected with similar freque...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5407341</comments>
            <pubDate>Tue, 08 Nov 2011 19:14:51 +0100</pubDate>
            <guid isPermaLink="false">5407341</guid>        </item>
        <item>
            <title>TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage</title>
            <link>http://www.medworm.com/index.php?rid=5400294&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh2g1462q05163149%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mantle cell lymphoma (MCL) is incurable in most patients. Several molecular markers have been identified as possible prognostic
 factors in MCL, including TP53 mutations. Direct sequencing was used to detect 32 cases with leukemic presentation of MCL
 form exons 2–11 in order to explore the prognostic significance of TP53 mutations in Chinese patients. Within the MCL cohort,
 6(18.8%) patients harbored TP53 mutations. TP53 mutations in the absence of del(17p13) were found in 5.0% of MCL cases (1
 of 20) compared with 83.3% of MCL cases (5 of 6) with del(17p13). Compared with patients without TP53 mutations, TP53 mutations
 were associated with risk factors including age, higher serum lactate dehydrogenase, lymphocytosis, high-risk (HR) international
 prognostic index,...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400294</comments>
            <pubDate>Sat, 05 Nov 2011 17:08:38 +0100</pubDate>
            <guid isPermaLink="false">5400294</guid>        </item>
        <item>
            <title>Association of clinical and pathological variables with survival in thymoma</title>
            <link>http://www.medworm.com/index.php?rid=5400295&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq3006517805157tk%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Our aim was to evaluate clinical and pathological features in prognosis of thymoma patients with particular emphasis on patients
 with myasthenia gravis (MG). From 1995 to 2010, 140 thymoma patients (women/men: 63/77) with a median age of 46&amp;nbsp;years (11–80&amp;nbsp;years)
 were admitted to our institution. According to World Health Organization (WHO), there were 23 (17%) type A, 12 (9%) type AB,
 24 (17%) type B1, 42 (31%) type B2 and 36 (26%) type B3. The distribution of Masaoka stages I, II, III and IV was 24 (17%),
 71 (51%), 18 (13%) and 27 (19%), respectively. MG coexisted in 61% of patients. After a mean follow-up of 34&amp;nbsp;months (1–158&amp;nbsp;months),
 102 (73%) patients are alive and well while 14 (10%) are alive with disease. Twenty-three patients (16%) have...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400295</comments>
            <pubDate>Sat, 05 Nov 2011 17:08:37 +0100</pubDate>
            <guid isPermaLink="false">5400295</guid>        </item>
        <item>
            <title>MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis</title>
            <link>http://www.medworm.com/index.php?rid=5400296&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4w70738h4104314g%2F</link>
            <description>In this study, using RT-PCR and further northern
 blot validation, we confirmed that miR-378 was significantly differentially expressed in the matched NSCLC from 8 patients
 with BM and 21 without BM. Our study showed evidences that miR-378 is associated with non-small cell lung cancer brain metastasis
 by promoting cell migration, invasion and tumor angiogenesis. MiR-378 may be a potential biomarker for characterizing non-small
 cell lung cancer brain metastasis and assisting clinicians in stratifying the high-risk patients on a clinical trial for either
 prophylactic cranial irradiation or a new intervention that may mitigate BM development, ultimately leading to a new standard
 of care for NSCLC patients.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-8DOI 10.1007/s1203...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400296</comments>
            <pubDate>Thu, 03 Nov 2011 16:57:06 +0100</pubDate>
            <guid isPermaLink="false">5400296</guid>        </item>
        <item>
            <title>Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=5400298&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F96j016260722u22k%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastric cancer remains a significant global health burden with poor treatment outcome. New treatment modalities that target
 inflammation, proliferation, and angiogenesis have been used in various cancers, including gastric cancer. We sought to study
 the pattern of expression of two important proteins, cyclooxygenase-2 and epidermal growth factor receptor, and their association
 with microvascular density, clinicopathological features, and survival in Arab Omani patients with gastric cancer. Formalin-fixed,
 paraffin-embedded tumors were studied by immunohistochemistry using monoclonal antibodies to cyclooxygenase-2, epidermal growth
 factor receptor, and CD34. The immunohistochemical results were correlated with clinicopathological features and survival.
 In our study...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400298</comments>
            <pubDate>Wed, 02 Nov 2011 16:45:28 +0100</pubDate>
            <guid isPermaLink="false">5400298</guid>        </item>
        <item>
            <title>Overexpression of AQP5 in cervical cancer: correlation with clinicopathological features and prognosis</title>
            <link>http://www.medworm.com/index.php?rid=5400297&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr934u40j583726v2%2F</link>
            <description>This study was to investigate the expression
 profile of AQP5 in cervical cancer and its clinical significance. We detected the expression profile of AQP5 mRNA and protein
 in cervical cancer tissue and in corresponding normal tissue by qRT-PCR and western blotting. Immunohistochemistry was also
 used in the detection of AQP5 protein expression as well as the proliferation index of Ki-67. The clinicopathological implications
 of these proteins were analyzed statistically. Survival analysis was performed to assess prognostic significance. AQP5 mRNA
 was overexpressed in cervical cancer tissue when compared with corresponding normal tissue, so was AQP5 protein. Overexpression
 of AQP5 was significantly associated with lymph node involvement (P&amp;nbsp;=&amp;nbsp;0.004). Overexpression of Ki-67 was ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400297</comments>
            <pubDate>Wed, 02 Nov 2011 16:45:28 +0100</pubDate>
            <guid isPermaLink="false">5400297</guid>        </item>
        <item>
            <title>Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen</title>
            <link>http://www.medworm.com/index.php?rid=5400299&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F02x462v68q673756%2F</link>
            <description>Content Type Journal ArticleCategory Case ReportPages 1-3DOI 10.1007/s12032-011-0090-yAuthors
		A. M. Tatli, Faculty of Medicine, Department of Internal Medicine, Medical Oncology, Akdeniz University, 07059 Konyaalti Antalya, TurkeyM. Uysal, Faculty of Medicine, Department of Internal Medicine, Medical Oncology, Akdeniz University, 07059 Konyaalti Antalya, TurkeyS. S. Goksu, Faculty of Medicine, Department of Internal Medicine, Medical Oncology, Akdeniz University, 07059 Konyaalti Antalya, TurkeyD. Arslan, Faculty of Medicine, Department of Internal Medicine, Medical Oncology, Akdeniz University, 07059 Konyaalti Antalya, TurkeyS. Gunduz, Faculty of Medicine, Department of Internal Medicine, Medical Oncology, Akdeniz University, 07059 Konyaalti Antalya, TurkeyM. Ozdogan, Faculty of Medici...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5400299</comments>
            <pubDate>Mon, 31 Oct 2011 17:02:21 +0100</pubDate>
            <guid isPermaLink="false">5400299</guid>        </item>
        <item>
            <title>Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5360054&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw07w504t1x1h0625%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas.
 The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We
 retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric
 and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2–3 cycles of preoperative
 docetaxel 75&amp;nbsp;mg/m2 and cisplatin 75&amp;nbsp;mg/m2 on day 1, 5-FU 750&amp;nbsp;mg/m2 (continuous infusion) on days 1–5 every 3&amp;nbsp;weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT
 scans. Overall survival (OS) and progression-free ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5360054</comments>
            <pubDate>Fri, 28 Oct 2011 06:01:11 +0100</pubDate>
            <guid isPermaLink="false">5360054</guid>        </item>
        <item>
            <title>Risk of nasopharyngeal carcinoma associated with polymorphic lactotransferrin haplotypes</title>
            <link>http://www.medworm.com/index.php?rid=5335248&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl1q4161p20p41435%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Lactotransferrin (LTF) is a component of the nonspecific immune system, having antimicrobial properties against bacteria,
 fungi, and several viruses. The gene coding for LTF is polymorphic, with the occurrence of several common alleles in the general
 population. Our previous study found that LTF inhibited nasopharyngeal carcinoma (NPC) cell proliferation in vitro and in
 vivo. To better understand one possible mechanism of LTF-mediated antitumor activity in NPC cells, in the present study, we
 investigated the distribution of LTF gene polymorphisms (rs1126477, rs1126478, rs2073495, and rs9110) in NPC and revealed
 whether these polymorphisms were associated with LTF gene expression. It was found that rs2073495 and rs9110 were correlated
 significantly with NPC. The fr...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335248</comments>
            <pubDate>Wed, 19 Oct 2011 15:46:37 +0100</pubDate>
            <guid isPermaLink="false">5335248</guid>        </item>
        <item>
            <title>The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5335247&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc3254634u3u144p6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Novel treatment strategies such as gene therapy are warranted in view of the failure of current treatment approaches to cure
 a high percentage of patients with advanced bladder cancers. The emergence of cancer gene therapy potentially offers a number
 of exciting treatments. The majority of approaches involve strategies to suppress the function of activated oncogenes to restore
 the expression of functional tumour suppressor genes or to initiate tumour self-destruction. One gene therapy approach against
 tumours that holds great promise is suicide gene therapy. Herpes simplex virus thymidine kinase (HSV-TK) phosphorylates ganciclovir
 (GCV), which in turn interacts with cellular DNA polymerase and interferes with DNA synthesis to cause death of rapidly dividing
 cells....</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335247</comments>
            <pubDate>Wed, 19 Oct 2011 15:46:37 +0100</pubDate>
            <guid isPermaLink="false">5335247</guid>        </item>
        <item>
            <title>Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma</title>
            <link>http://www.medworm.com/index.php?rid=5335249&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm8484800l472n95n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Previous studies have demonstrated that the expression of prostate-specific membrane antigen (PSMA) is restricted to endothelium
 from tumor-associated neovasculature. But the expression of PSMA in osteosarcoma and its clinical significance are unknown.
 Using immunohistochemical analysis and quantum dot probes, we found that 46.7% (21/45) of the osteosarcoma showed positive
 staining for PSMA while no PSMA staining in osteofibrous dysplasia. The expression and localization of PSMA was confirmed
 by CD34 staining. More importantly, the expression of PSMA is correlated with tumor size, pulmonary metastasis and worse survival
 (survival rate 63.2% in the PSMA-negative group versus 36.6% in the PSMA-positive group). Thus, PSMA could be used as an independent
 prognostic ma...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335249</comments>
            <pubDate>Wed, 19 Oct 2011 05:56:47 +0100</pubDate>
            <guid isPermaLink="false">5335249</guid>        </item>
        <item>
            <title>MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance</title>
            <link>http://www.medworm.com/index.php?rid=5323788&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgh3491682681562p%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recently, accumulating evidence indicates that dysregulation of miRNAs is associated with the initiation and progression of
 cancer. MiR-101 has been reported down-regulated in various types of cancer. The aim of this study was to investigate the
 expression profile of miR-101 and its target gene Mcl-1 in NSCLC and to assess their clinical significance. QRT-PCR was used
 in the detection of miR-101 and Mcl-1 mRNA expression both in NSCLC tissue and in adjacent normal lung tissue. Immunohistochemistry
 and Western blot analysis were used in the detection of Mcl-1 protein expression. The clinicopathological implications of
 these molecules were analyzed statistically. Survival analysis was performed to assess prognostic significance. Down-regulation
 of miR-101 was associ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5323788</comments>
            <pubDate>Thu, 13 Oct 2011 05:47:52 +0100</pubDate>
            <guid isPermaLink="false">5323788</guid>        </item>
        <item>
            <title>Cerebellar glioneuronal tumor: a case report and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=5323789&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy807063h5w8j455j%2F</link>
            <description>Content Type Journal ArticleCategory Review ArticlePages 1-2DOI 10.1007/s12032-011-0078-7Authors
		Ali Mahta, Department of Neurosciences, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USAEwa Borys, Department of Neurosciences, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USASantosh Kesari, Department of Neurosciences, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5323789</comments>
            <pubDate>Thu, 13 Oct 2011 05:47:51 +0100</pubDate>
            <guid isPermaLink="false">5323789</guid>        </item>
        <item>
            <title>Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5314006&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq602k7r6785q6h60%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hepatocellular carcinoma (HCC) is usually diagnosed in advanced stage, which causes difficulty of using surgical treatment.
 Previous studies demonstrated that tyroserleutide (YSL), an immunologically active&amp;nbsp;tripeptide compound, could suppress the
 proliferation and tumor formation of some liver cancer cell lines. We aimed to investigate the feasibility and toxicity of
 continuous administration of YSL by a portable infusion pump to patients with advanced HCC and its biologically effective
 but non-toxic doses used in outpatient setting. Forty patients (12 in stage 1, 28 in stage 2, total 10 treated in each dose
 cohort) were treated with YSL 6, 12, 18, or 24&amp;nbsp;mg/day lasting for 5&amp;nbsp;days. No treatment-related mortality was observed. The
 overall response rat...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5314006</comments>
            <pubDate>Tue, 11 Oct 2011 05:48:21 +0100</pubDate>
            <guid isPermaLink="false">5314006</guid>        </item>
        <item>
            <title>Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5314007&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F04g843xx4n208181%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Microarray data suggested that the expression of aldehyde dehydrogenase 1 family member L1 (ALDH1L1) is reduced in hepatocellular
 carcinoma (HCC). However, the role of ALDH1L1 in HCC carcinogenesis has not been elucidated. In the present study, we investigated
 the expression of ALDH1L1 in HCC and evaluated its relationship with clinical features and prognosis of HCC patients. Total
 112 tumor samples were collected from patients with HCC, who underwent radical hepatectomy. Out of the 112 samples, 16 paired
 HCC tumorous and corresponding adjacent nontumor tissues were analyzed by real-time quantitative RT-PCR (qRT-PCR) and Western
 blotting, and the other 96 HCC samples were detected by immunohistochemical method. The qRT-PCR assay showed that the mRNA
 level of ALDH1...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5314007</comments>
            <pubDate>Tue, 11 Oct 2011 05:48:19 +0100</pubDate>
            <guid isPermaLink="false">5314007</guid>        </item>
        <item>
            <title>Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis</title>
            <link>http://www.medworm.com/index.php?rid=5314008&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk3m6583714541073%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A disintegrin and metalloprotease 8 (ADAM8) has been shown to be expressed in various cancer types, and its expression was
 associated with advanced progression of several tumors. However, little is known about ADAM8 in human gliomas. Therefore,
 we here evaluated the correlation of ADAM8 expression with the clinicopathological features and prognosis in the patients
 with gliomas. Immunohistochemistry and western blot were used to investigate the expression of ADAM8 protein, respectively,
 in 128 patients with gliomas. The expression levels of ADAM8 in glioma tissues were significantly higher (P&amp;nbsp;=&amp;nbsp;0.002) than those in non-neoplastic brain tissues according to the immunohistochemistry analysis. In addition, a high level
 of ADAM8 expression was significantly mo...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5314008</comments>
            <pubDate>Sat, 08 Oct 2011 15:43:22 +0100</pubDate>
            <guid isPermaLink="false">5314008</guid>        </item>
        <item>
            <title>Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304135&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp4u112736h267w11%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary breast invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) is characterized by lower proliferation
 rate and metastatic propensity than size-matched pure IDC. IDC-DCIS is also more often ER-positive, PR-positive and/or HER2-positive.
 This analysis aims to clarify whether the presence of coexisting DCIS in IDC affects tumor aggressiveness in various biological
 subtypes of breast cancer, respectively. Tumor data obtained from 1,355 consecutive female patients undergoing upfront surgery
 for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that
 immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into
 4 gro...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304135</comments>
            <pubDate>Fri, 07 Oct 2011 16:00:29 +0100</pubDate>
            <guid isPermaLink="false">5304135</guid>        </item>
        <item>
            <title>Urban and non-urban disparities in the use of post-mastectomy radiation for breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304134&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F836g11337834l4q5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Post-mastectomy radiation therapy (PMRT) is indicated for local-regionally advanced breast cancer (LABC). We hypothesized
 that candidates for PMRT from non-urban areas would receive lower rates of RT than urban patients and would have poorer overall
 survival (OS) and disease-specific survival (DSS). We used the Surveillance, Epidemiology, and End Results database to identify
 patients diagnosed with LABC and treated with mastectomy in Sacramento and its surrounding 13 counties between 2000 and 2006.
 All patients were eligible to receive RT according to established guidelines, with tumors &amp;gt;5&amp;nbsp;cm size, ≥4 metastatic lymph
 nodes, or both. According to a United States Department of Agriculture scale, we designated counties as urban or non-urban
 and used multiv...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304134</comments>
            <pubDate>Fri, 07 Oct 2011 16:00:29 +0100</pubDate>
            <guid isPermaLink="false">5304134</guid>        </item>
        <item>
            <title>Genetic alterations of the WWOX gene in breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304137&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn7q6364703388r28%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;FRA3B and FRA16D are the most sensitive common chromosomal fragile site loci in the human genome and two tumor suppressor
 genes FHIT (Fragile Histidine Triad) and WWOX (WW domain-containing oxidoreductase gene) map to this sites. The WWOX gene
 is composed of 9 exons and encodes a 46-kD protein that contains 414 amino acids. Loss of heterozygosity, homozygous deletions,
 and chromosomal translocations affecting WWOX has been reported in several types of cancer, including ovarian, esophageal,
 lung and stomach carcinoma, and multiple myeloma. The aim of this study was to determine the role of WWOX as a tumor suppressor
 gene in patients with breast cancer. Tumor and adjacent non-cancerous tissue samples were obtained from 81 patients with breast
 cancer. DNA was isolate...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304137</comments>
            <pubDate>Fri, 07 Oct 2011 16:00:28 +0100</pubDate>
            <guid isPermaLink="false">5304137</guid>        </item>
        <item>
            <title>Leptomeningeal carcinomatosis from ovarian cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304136&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx26k346u8u0351q1%2F</link>
            <description>We report a case of a woman with metastatic ovarian cancer who developed
 leptomeningeal carcinomatosis while receiving systemic chemotherapy. We also provide an extensive review of the existing literature
 on neoplastic meningitis from ovarian cancer.
 
 
	Content Type Journal ArticleCategory Review ArticlePages 1-6DOI 10.1007/s12032-011-0076-9Authors
		Eliza Miller, Columbia University College of Physicians and Surgeons, 2012 630 West 168th St, New York, NY 10032, USAIrene Dy, Department of Hematology-Oncology, St. Luke’s Roosevelt Hospital, 1000 Tenth Avenue 11G, New York, NY 10019, USAThomas Herzog, Division of Gynecologic Oncology, Columbia University Medical Center, New York, NY, USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304136</comments>
            <pubDate>Fri, 07 Oct 2011 16:00:28 +0100</pubDate>
            <guid isPermaLink="false">5304136</guid>        </item>
        <item>
            <title>Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis</title>
            <link>http://www.medworm.com/index.php?rid=5296696&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9341573u6142j4m4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The molecular mechanisms leading to gastric carcinogenesis still remain unclear. Recently, several studies demonstrated that
 over-expression of guanylyl cyclase C (GCC) has been detected in intestinal-type gastric cancer (GC) and precursor lesions.
 Our objective was to explore the expression levels of GCC and endogenous ligands guanylin (GN) and uroguanylin (UGN) and the
 correlation between Helicobacter pylori (H. pylori) and GCC, GN, and UGN expressions in patients at different stages from normal mucosa to superficial gastritis, atrophic gastritis,
 intestinal metaplasia (IM), dysplasia, and finally adenocarcinoma. The expression of GCC and GN was absent in the distal normal
 gastric tissues and superficial gastritis in all cases, whereas they were measured in IM, d...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5296696</comments>
            <pubDate>Wed, 05 Oct 2011 05:49:20 +0100</pubDate>
            <guid isPermaLink="false">5296696</guid>        </item>
        <item>
            <title>Sequential therapy in metastatic renal cell carcinoma: what comes next?</title>
            <link>http://www.medworm.com/index.php?rid=5285226&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F51p221h8v01g654p%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorPages 1-2DOI 10.1007/s12032-011-0073-zAuthors
		Camillo Porta, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, ItalyThomas Powles, St. Bartholomew’s Hospital London, London, UK
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5285226</comments>
            <pubDate>Sat, 01 Oct 2011 06:44:48 +0100</pubDate>
            <guid isPermaLink="false">5285226</guid>        </item>
        <item>
            <title>Folate metabolism-related gene polymorphisms and susceptibility to primary liver cancer in North China</title>
            <link>http://www.medworm.com/index.php?rid=5285227&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft1r330nj1048675r%2F</link>
            <description>This study was designed to investigate
 the effects of the polymorphisms of methylenetetrahydrofolate reductase 677 C&amp;nbsp;→&amp;nbsp;T (MTHFR 677 C&amp;nbsp;→&amp;nbsp;T), methylenetetrahydrofolate
 reductase 1298 A&amp;nbsp;→&amp;nbsp;C (MTHFR 1298A&amp;nbsp;→&amp;nbsp;C), thymidylate synthase (TYMS 3R&amp;nbsp;→&amp;nbsp;2R), and methionine synthase 2756 A&amp;nbsp;→&amp;nbsp;G (MTR 2756
 A&amp;nbsp;→&amp;nbsp;G) on the risk of primary liver cancer (PLC). We conducted a case–control study involving 356 PLC cases and 641 healthy
 controls in North China. Compared with the MTHFR 677CC genotype, the MTHFR 677TT genotype showed an increased risk for PLC
 (TT vs. CC: adjusted odds ratio (OR)&amp;nbsp;=&amp;nbsp; 1.56; 95% confidence interval (CI): 1.02–2.40; P&amp;nbsp;=&amp;nbsp;0.043) after adjusting for gender and age, whereas the MTHFR ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5285227</comments>
            <pubDate>Thu, 29 Sep 2011 06:06:44 +0100</pubDate>
            <guid isPermaLink="false">5285227</guid>        </item>
        <item>
            <title>Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs</title>
            <link>http://www.medworm.com/index.php?rid=5273361&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa45837112wp80p04%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastrointestinal stromal tumors (GISTs) are the most common human sarcoma. Most of the data available on GISTs derive from
 retrospective studies of patients referred to oncology centers. The MolecGIST study sought to determine and correlate clinicopathological
 and molecular characteristics of GISTs. Tumor samples and clinical records were prospectively obtained and reviewed for patients
 diagnosed in France during a 24-month period. Five hundred and ninety-six patients were included, of whom 10% had synchronous
 metastases. GISTs originated from the stomach, small bowel or other site in 56.4, 30.2 and 13.4% of cases, respectively. The
 main prognostic markers, tumor localization, size and mitotic index were not independent variables (P&amp;nbsp;&amp;lt;&amp;nbsp;0.0001). Mutation...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5273361</comments>
            <pubDate>Wed, 28 Sep 2011 05:52:34 +0100</pubDate>
            <guid isPermaLink="false">5273361</guid>        </item>
        <item>
            <title>Expression of Plakophilins (PKP1, PKP2, and PKP3) in breast cancers</title>
            <link>http://www.medworm.com/index.php?rid=5260250&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu31r6x1u5r771762%2F</link>
            <description>Conclusion: Overexpressed PKP3 is likely to be an essential contributor to a growth-promoting pathway and to aggressive
 features of breast cancer.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-5DOI 10.1007/s12032-011-0071-1Authors
		Guzin Gonullu Demirag, Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayıs University, Kurupelit, Samsun, 55139 TurkeyYurdanur Sullu, Department of Pathology, Faculty of Medicine, Ondokuz Mayıs University, Kurupelit, Samsun, 55139 TurkeyIdris Yucel, Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayıs University, Kurupelit, Samsun, 55139 Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260250</comments>
            <pubDate>Sun, 25 Sep 2011 05:37:08 +0100</pubDate>
            <guid isPermaLink="false">5260250</guid>        </item>
        <item>
            <title>GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5260251&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft4022145kx2137t1%2F</link>
            <description>In conclusion, the GEMOX regimen is
 well tolerated and effective in advanced differentiated thyroid cancer. However, this retrospective data on a small sample
 size are considered preliminary and needs to be evaluated prospectively in a higher number of patients in a clinical trial.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-8DOI 10.1007/s12032-011-0070-2Authors
		Jean-Philippe Spano, Medical Oncology Department, GH Pitié-Salpêtrière, Université Paris 6, Paris, FranceY. Vano, Medical Oncology Department, GH Pitié-Salpêtrière, Université Paris 6, Paris, FranceS. Vignot, Medical Oncology Department, GH Pitié-Salpêtrière, Université Paris 6, Paris, FranceT. De La Motte Rouge, Medical Oncology Department, GH Pitié-Salpêtrière, Université Paris 6, Paris, Fr...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260251</comments>
            <pubDate>Sun, 25 Sep 2011 05:37:07 +0100</pubDate>
            <guid isPermaLink="false">5260251</guid>        </item>
        <item>
            <title>Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5260252&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk35116p035524n77%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study is to elucidate the prognostic significance of thymidylate synthase (TS), orotate phosphoribosyltransferase
 (OPRT) and dihydropyrimidine dehydrogenase (DPD) in completely resected non-small cell lung cancer (NSCLC). One hundred and
 sixty patients with NSCLC were included in this study. Tumor sections were stained by immunohistochemistry for TS, OPRT, DPD,
 glucose transporter 1 (Glut1), hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), microvessel
 density (MVD) determinated by CD34, epidermal growth factor receptor (EGFR), phosph-Akt, phosph-mammalian target of rapamycin
 (mTOR) and p53. TS, OPRT and DPD were positively expressed in 46, 71 and 54%, respectively. The expression of TS and OPRT
 was significantly hi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260252</comments>
            <pubDate>Fri, 23 Sep 2011 16:19:40 +0100</pubDate>
            <guid isPermaLink="false">5260252</guid>        </item>
        <item>
            <title>Mantle cell lymphoma successfully treated in a patient with multiple endocrine neoplasia type 2: a rare combination of two malignancies</title>
            <link>http://www.medworm.com/index.php?rid=5260254&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh1ng4q1746528256%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorPages 1-2DOI 10.1007/s12032-011-0072-0Authors
		Maciej Machaczka, Division of Hematology, Department of Medicine at Huddinge, Karolinska Institute, and Hematology Center Karolinska, M54, Karolinska University Hospital Huddinge, Stockholm, Sweden
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260254</comments>
            <pubDate>Fri, 23 Sep 2011 05:54:30 +0100</pubDate>
            <guid isPermaLink="false">5260254</guid>        </item>
        <item>
            <title>Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity</title>
            <link>http://www.medworm.com/index.php?rid=5260253&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh64j1582w52p0450%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Angiogenesis is the new blood vessels formation and is the critical event for the growth of malignant diseases and plays a
 key role in the development, invasion, and metastasis of malignant tumors. Epstein-Barr virus (EBV) is an important carcinogen
 causing to the some neoplastic disorders and lytically infected cells may contribute to the growth of EBV-associated malignancies,
 and this phenomenon is related with enhancing angiogenesis. Due to the strong cross-talk between angiogenesis and viral carcinogenesis
 and increased information about the angiogenesis and viral carcinogenesis in lymphomas, we need new therapeutic approaches
 to cases with lymphoma. Due to the strong cross-talk between angiogenesis and viral lymphomagenesis, this association was
 reviewed in t...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5260253</comments>
            <pubDate>Fri, 23 Sep 2011 05:54:30 +0100</pubDate>
            <guid isPermaLink="false">5260253</guid>        </item>
        <item>
            <title>Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival</title>
            <link>http://www.medworm.com/index.php?rid=5236879&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F05952347m0306248%2F</link>
            <description>The objective response rate of was 42.64% in the VC-APS arm and 36.76% in the VC arm. The difference was not statistically
 significant (P&amp;nbsp;=&amp;nbsp;0.483). Median survival time was 10.7 and 10.2&amp;nbsp;months (P&amp;nbsp;=&amp;nbsp;0.76) in VC-APS arm and VC arm, with 1-year survival rates of 35.3 and 32.4% (P&amp;nbsp;=&amp;nbsp;0.717), respectively. After 3&amp;nbsp;cycles of treatment, there were significant differences in the overall patient QOL (P&amp;nbsp;=&amp;nbsp;0.003), physical function (P&amp;nbsp;=&amp;nbsp;0.01), fatigue (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001), nausea and vomiting (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001), pain (P&amp;nbsp;=&amp;nbsp;0.007), and loss of appetite (P&amp;nbsp;=&amp;nbsp;0.023) between the two study groups. In summary, we have proved that the treatment of APS integrated with VC had significantly
 improved QOL in patients with ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5236879</comments>
            <pubDate>Sat, 17 Sep 2011 17:06:54 +0100</pubDate>
            <guid isPermaLink="false">5236879</guid>        </item>
        <item>
            <title>An association between corticosteroid use and melanoma recurrence: a case report and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=5236880&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjr02620q326540x0%2F</link>
            <description>Content Type Journal ArticleCategory Case ReportPages 1-3DOI 10.1007/s12032-011-0064-0Authors
		Mark Lazarus, Rush Medical College, Rush University, Chicago, IL, USAHoward Kaufman, Department of Surgical Oncology, Faculty of Medicine, Rush University, Chicago, IL, USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5236880</comments>
            <pubDate>Fri, 16 Sep 2011 05:45:15 +0100</pubDate>
            <guid isPermaLink="false">5236880</guid>        </item>
        <item>
            <title>Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein–Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil</title>
            <link>http://www.medworm.com/index.php?rid=5236881&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F280k57u175885nt5%2F</link>
            <description>In this study, we evaluated the prognostic
 relevance of MMP9 expression and EBV status in HRS cells in patients with cHL in Brazil. We selected 97 patients with cHL
 for EBV and MMP9 detection. EBV was detected in 52.5%, and MMP9 expression positivity was found in 87.6%. Of all cases, there
 was no correlation between MMP9 expression and EBV status. Response to treatment and relapse rate was independent of MMP9
 expression and EBV status. MMP9 positivity did not influence overall survival and event-free survival. The consistent and
 increased intensity of MMP9 expression in HRS cells make this enzyme a potential target for therapy.
 
 
	Content Type Journal ArticleCategory Short CommunicationPages 1-5DOI 10.1007/s12032-011-0063-1Authors
		Eni M. Souza, Departamento de Oncologia Clínica e...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5236881</comments>
            <pubDate>Fri, 16 Sep 2011 05:45:14 +0100</pubDate>
            <guid isPermaLink="false">5236881</guid>        </item>
        <item>
            <title>Loss of Bad expression confers poor prognosis in non-small cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=5236882&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc26664435276m815%2F</link>
            <description>In conclusion, this study provided clinical evidence that loss of Bad is an independent and powerful predictor of
 adverse prognosis in NSCLC. Bad protein could be a new biomarker for selecting individual therapy strategies and predicting
 therapeutic response in subjects with NSCLC.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-8DOI 10.1007/s12032-011-0060-4Authors
		Yi Huang, Laboratory of Genetic Disease and Perinatal Medicine, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaDan Liu, Department of Respiratory Medicine, West China Hospital, Sichuan University, 610041 Chengdu, People’s Republic of ChinaBojiang Chen, Department of Respiratory Medicine, West China Hospital, Sichuan University, 610041 Chengdu, People’s Rep...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5236882</comments>
            <pubDate>Thu, 15 Sep 2011 05:49:20 +0100</pubDate>
            <guid isPermaLink="false">5236882</guid>        </item>
        <item>
            <title>High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker</title>
            <link>http://www.medworm.com/index.php?rid=5224974&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn69k1237l4731008%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;S100A11 is a member of S100 protein family, and our previous study showed that S100A11 is one of the up-regulated proteins
 that have not been reported to be associated with pancreatic carcinoma. The purpose of this study was to investigate the relation
 between S100A11 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma.
 Immunohistochemistry analysis was performed for S100A11 in 78 pairs of specimens of human pancreatic adenocarcinoma tissues
 and adjacent nontumorous tissues. The univariate and multivariate survival analyses were also performed to determine its prognostic
 significance. S100A11 expression in pancreatic adenocarcinoma (62/78) was significantly higher than that in the adjacent nontumorous
 ti...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5224974</comments>
            <pubDate>Tue, 13 Sep 2011 05:48:51 +0100</pubDate>
            <guid isPermaLink="false">5224974</guid>        </item>
        <item>
            <title>Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5224976&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8160568723836x38%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to evaluate the expression of Y-box binding protein-1 (YB-1) in nonneoplastic cervical tissue and
 cervical cancer tissue and to evaluate its relationship with chemoradiosensitivity in the cases of cervical cancer. We performed
 immunohistochemical studies to examine YB-1 expression among 59 patients with cervical cancer, 30 with cervical intraepithelial
 neoplasia (CIN), and 30 with cervicitis. The mean YB-1 histological score(HSCORE)values for cervicitis, cervical CIN, and
 cervical cancer tissues were 22.3, 39, and 84.4, respectively. The mean YB-1 HSCORE value was 80.0 for cervical cancer patients
 who showed complete pathological response to chemoradiotherapy and 144.3 for cervical cancer patients who showed partial pathological
 response....</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5224976</comments>
            <pubDate>Sat, 10 Sep 2011 15:46:35 +0100</pubDate>
            <guid isPermaLink="false">5224976</guid>        </item>
        <item>
            <title>Absence of human papillomavirus sequences in epithelial breast cancer in a Mexican female population</title>
            <link>http://www.medworm.com/index.php?rid=5224975&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F083431467kt9t8g0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of human papillomavirus (HPV) in breast cancer is controversial. We evaluated 118 breast carcinomas and two paraffin-embedded
 tissues of lesions of the nipple of Mexican patients for HPV sequences. No carcinoma sample exhibited koilocytosis, in contrast
 to lesions of the nipple. We subjected purified DNAs to PCR employing two HPV16/E6 or GP5/6 primer set oligonucleotides. Results
 showed that HPV DNA sequences were absent in the breast tissues. Absence of HPV in breast carcinoma failed to support an association
 between HPV infection and this carcinoma.
 
 
	Content Type Journal ArticleCategory Short CommunicationPages 1-3DOI 10.1007/s12032-011-0059-xAuthors
		Lisbeth Herrera-Romano, División de Investigación en Salud, Unidad Médica de Alta Especialidad (U...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5224975</comments>
            <pubDate>Sat, 10 Sep 2011 15:46:35 +0100</pubDate>
            <guid isPermaLink="false">5224975</guid>        </item>
        <item>
            <title>Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient</title>
            <link>http://www.medworm.com/index.php?rid=5224977&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy01jp000pl450333%2F</link>
            <description>We examined the Nedd4L expression in 82 gastric cancer patients by immunohistochemistry. The correlation between Nedd4L expression
 and clinicopathological factors, including prognosis, was evaluated. Cancerous Nedd4L expression was detectable in 36 of the
 82 tumors (43.9%). Tumors with negative Nedd4L expression had greater extent of lymph node metastasis, lymphatic invasion,
 and venous invasion, and were at a worse stage than the tumors with positive Nedd4L expression. Additionally, the patients
 with negative Nedd4L expression had poor clinical outcomes. Furthermore, multivariate analysis indicated that Nedd4L expression
 was an independent prognostic factor for gastric cancer patients. Our results suggest for the first time that negative Nedd4L
 expression is strongly related to the ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5224977</comments>
            <pubDate>Sat, 10 Sep 2011 15:46:34 +0100</pubDate>
            <guid isPermaLink="false">5224977</guid>        </item>
        <item>
            <title>Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population</title>
            <link>http://www.medworm.com/index.php?rid=5208079&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd1555r310h118236%2F</link>
            <description>In conclusion,
 the present study indicates that the GPX1 Pro198Leu polymorphism may be associated with the risk and development of invasive
 bladder cancer. In addition, the combination of the MnSOD Ala/Ala and GPX1 Leu/Leu genotypes may have a synergistic effect
 on disease risk.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-7DOI 10.1007/s12032-011-0057-zAuthors
		Canan Kucukgergin, Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, TurkeyOner Sanli, Department of Urology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, TurkeyAkın S. Amasyalı, Department of Urology, Istanbul Teaching and Research Hospital, 34098 Istanbul, TurkeyTzevat Tefik, Department of Urology, Istanbul Faculty of Medicine, Istanbul Uni...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5208079</comments>
            <pubDate>Fri, 09 Sep 2011 05:49:20 +0100</pubDate>
            <guid isPermaLink="false">5208079</guid>        </item>
        <item>
            <title>Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome</title>
            <link>http://www.medworm.com/index.php?rid=5208080&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flt30l0p7x5575403%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Approximately 10% of colorectal carcinomas demonstrate microsatellite instability (MSI). Distinct from the majority of colorectal
 cancers with chromosomal instability (CIN) which harbour allelic imbalance from chromosomal polyploidy and aneuploidy, MSI
 tumours retain intact chromosomal numbers but contain microsatellite repeats due to deficiency in mismatch repair which are
 thought to contribute to the early steps of tumourigenesis in colorectal cancer. While emerging clinical data has highlighted
 improved prognosis of tumours with MSI in early colorectal cancer and potentially circumventing the need for adjuvant chemotherapy,
 the implications of MSI deficiency in metastatic colorectal cancer (mCRC) remain uncertain. In order to assess the significance
 of MSI in m...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5208080</comments>
            <pubDate>Thu, 08 Sep 2011 05:55:29 +0100</pubDate>
            <guid isPermaLink="false">5208080</guid>        </item>
        <item>
            <title>Primary malignant melanoma of the female urethra: 10-year survival</title>
            <link>http://www.medworm.com/index.php?rid=5208081&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn442r2010r414243%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorPages 1-2DOI 10.1007/s12032-011-0055-1Authors
		Silvio Altarac, Department of Surgery and Urology, Zabok General Hospital, Bračak 8, 49210 Zabok, CroatiaDino Papeš, Department of Surgery and Urology, Zabok General Hospital, Bračak 8, 49210 Zabok, Croatia
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5208081</comments>
            <pubDate>Sun, 04 Sep 2011 10:57:03 +0100</pubDate>
            <guid isPermaLink="false">5208081</guid>        </item>
        <item>
            <title>Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide</title>
            <link>http://www.medworm.com/index.php?rid=5183480&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fppn0mw6443mg105l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To determine whether prognostic factors remain relevant to chronic lymphocytic leukemia (CLL) patients treated with fludarabine
 and cyclophosphamide (FC), we prospectively evaluated 86 Chinese CLL patients who received FC in first-line therapy. Twenty-four
 patients (27.9%) achieved complete remission (CR), and overall response rate was 75.6%. With a median follow-up of 41&amp;nbsp;months,
 the median progression-free survival (PFS) was 36.0&amp;nbsp;months and median overall survival (OS) has not been reached. The strong
 correlations of lower CR rate with advanced Binet stage, unmutated IGHV, cytogenetic abnormalities of del(17p13) or del(11q23),
 and p53 mutations were observed by univariable analyses. Stepwise logistic regression identified that unmutated IGHV and p53
 abn...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183480</comments>
            <pubDate>Wed, 31 Aug 2011 15:54:07 +0100</pubDate>
            <guid isPermaLink="false">5183480</guid>        </item>
        <item>
            <title>Leptin and breast cancer: an overview</title>
            <link>http://www.medworm.com/index.php?rid=5183481&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3442827036534553%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Leptin is a well-known mediator of obesity. Leptin and its receptor are overexpressed in breast cancer, especially in high-grade
 tumors. It has an association with progression and poor survival of breast cancer. Leptin can regulate endothelial cell proliferation
 and promote angiogenesis. There are several other factors such as insulin and HER2 may be involved in the relationship between
 leptin and breast cancer. Leptin system has emerged as a new and promising therapeutic target for breast cancer. This review
 article summarizes the current knowledge about the relation of leptin and breast cancer.
 
 
	Content Type Journal ArticleCategory Review ArticlePages 1-5DOI 10.1007/s12032-011-0056-0Authors
		Mehmet Artac, Division of Medical Oncology, Selcuk University Meram ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183481</comments>
            <pubDate>Tue, 30 Aug 2011 05:41:50 +0100</pubDate>
            <guid isPermaLink="false">5183481</guid>        </item>
        <item>
            <title>Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5183482&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp2m65528568k3803%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The present study examines the clinical significance of serum neuron-specific enolase (NSE) in patients with non-germinal
 center B-cell type (non-GCB) of diffuse large B-cell lymphoma (DLBCL) that received rituximab chemotherapy. Serum NSE values
 were measured using electrochemiluminescence assay in 53 patients. About 54.7% of the DLBCL patients had positive expression
 of serum NSE (&amp;gt;15.20&amp;nbsp;ng/ml), which closely correlated with performance status, serum LDH level, B symptoms, IPI scores, and
 Ann-Arbor stages (P&amp;nbsp;&amp;lt;&amp;nbsp;0.05). The mean serum NSE value in patients with non-GCB subtype of DLBCL was significantly higher than that of GCB subtype
 of DLBCL (P&amp;nbsp;=&amp;nbsp;0.001), and among patients in non-GCB subtype group, there was significant difference in...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183482</comments>
            <pubDate>Mon, 29 Aug 2011 16:00:01 +0100</pubDate>
            <guid isPermaLink="false">5183482</guid>        </item>
        <item>
            <title>CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis</title>
            <link>http://www.medworm.com/index.php?rid=5183483&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg38l8853541wx1m6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cancerous inhibitor of protein phosphatase 2A (CIP2A) and survivin are aberrantly expressed in a wide range of human cancers,
 including lung tumors. In order to assess the expressions of these two proteins in Chinese non-small-cell lung cancer (NSCLC)
 patients and determine their correlation with prognosis, NSCLC tissues and adjacent non-cancerous normal lung tissues were
 collected from 97 patients undergoing surgical treatment and evaluated by immunohistochemistry staining. CIP2A or survivin
 immunoreactivity was detected in significantly more NSCLC tissues than in adjacent non-cancerous lung tissues (P&amp;nbsp;&amp;lt;&amp;nbsp;0.05). Moreover, CIP2A expression in NSCLC correlated with TNM stage, while survivin expression correlated with TNM stage
 and lymph node metastasis. ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5183483</comments>
            <pubDate>Sun, 28 Aug 2011 05:36:25 +0100</pubDate>
            <guid isPermaLink="false">5183483</guid>        </item>
        <item>
            <title>Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China</title>
            <link>http://www.medworm.com/index.php?rid=5175533&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx3843791t850740x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;As a main effector in the renin-angiotensin system, the angiotensin II plays a critical role in cell proliferation and angiogenesis.
 The change between angiotensin II and its precursor is conducted by the angiotensin-converting enzyme. The association between
 angiotensin-converting enzyme insertion/deletion polymorphism and the activity of angiotensin-converting enzyme was testified.
 Furthermore, previous researches proved the association between angiotensin-converting enzyme activity and the risk of prostate
 cancer. Therefore, we conducted a case–control study in the Han population of China to elaborate the relation between the
 angiotensin-converting enzyme insertion/deletion polymorphism and prostate cancer. DNA was extracted from blood samples collected
 from ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175533</comments>
            <pubDate>Sat, 27 Aug 2011 15:48:30 +0100</pubDate>
            <guid isPermaLink="false">5175533</guid>        </item>
        <item>
            <title>Letter to the editor regarding the article by Uzunoglu et al</title>
            <link>http://www.medworm.com/index.php?rid=5175534&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm1262652l0790581%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorPages 1-1DOI 10.1007/s12032-011-0052-4Authors
		Yasemin Savranlar, Department of Histology and Embryology, Faculty of Medicine, Erciyes University, 38039 Kayseri, TurkeyMehmet Fatih Sönmez, Department of Histology and Embryology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175534</comments>
            <pubDate>Sat, 27 Aug 2011 15:48:28 +0100</pubDate>
            <guid isPermaLink="false">5175534</guid>        </item>
        <item>
            <title>Increased serum level of Nup88 protein is associated with the development of colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=5161205&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu42p60u438400845%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nucleoporin88 (Nup88) has been shown to be overexpressed in a wide variety of malignancies including colorectal cancer (CRC).
 However, no study about serum Nup88 in human CRC was reported. Therefore, in this study, we investigated the level of serum
 Nup88 protein and its relationships with clinicopathological variables in CRC. The serum concentration of Nup88 protein was
 determined by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) in 118 pre-operative serum samples, 66 post-operative
 and 96 healthy controls. Among the patients, the levels of CEA (n&amp;nbsp;=&amp;nbsp;91) and CA19-9 (n&amp;nbsp;=&amp;nbsp;87) in the pre-operative serum were measured, and DNA sequencing was performed in 12 CRCs and 2 samples from non-cancerous
 colon tissue. In the same patients, ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161205</comments>
            <pubDate>Wed, 24 Aug 2011 07:18:40 +0100</pubDate>
            <guid isPermaLink="false">5161205</guid>        </item>
        <item>
            <title>Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results</title>
            <link>http://www.medworm.com/index.php?rid=5161206&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa3570127237t5961%2F</link>
            <description>In this study, we analyzed the correlation between expression of PGP and
 lymphoid antigens (Ly) on leukemic myeloblasts versus response to therapy and survival in acute myeloid leukemia (AML). Fifty-one
 consecutive patients, aged 16–75 (median age 44.6&amp;nbsp;years), diagnosed with de novo AML between 1997 and 2000, and who received at least one induction chemotherapy course, were enrolled in the study. Expression
 of PGP on ≥10% of the myeloblasts (PGP+AML) at the time of diagnosis was observed in 21 patients (41%). The complete remission rate did not differ between PGP+ (13/21) and PGP− (20/30) patients (62 vs. 67%). Twelve of the 51 patients (24%) were still alive after a median follow-up time of 11.5&amp;nbsp;years (range 10.7–13.1). The
 Ly+AML patients showed significantly better...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161206</comments>
            <pubDate>Tue, 23 Aug 2011 05:57:12 +0100</pubDate>
            <guid isPermaLink="false">5161206</guid>        </item>
        <item>
            <title>Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=5161207&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh63375477p784232%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The present study was aimed at evaluating the expression of heat shock protein 27 (HSP27) and heterogeneous nuclear ribonucleoprotein
 K (hnRNP K), two potential biomarkers of many cancers, in colorectal cancer (CRC) and their clinical significance. Expression
 of HSP27 and hnRNP K were investigated by immunohistochemistry (IHC) in a series of tissue microarrays containing 175 primary
 colorectal cancers and their corresponding normal mucosa samples and matched with clinicopathological features and patient
 survival. HSP27 and hnRNP K displayed more frequent strong immunoreactivity in primary colorectal tumor samples compared with
 adjacent non-cancer tissue (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). Increased cytoplasmic expression of HSP27 and hnRNP K were associated with tumor locati...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161207</comments>
            <pubDate>Tue, 23 Aug 2011 05:57:11 +0100</pubDate>
            <guid isPermaLink="false">5161207</guid>        </item>
        <item>
            <title>Cytokine and endocrine signaling in prostate cancer</title>
            <link>http://www.medworm.com/index.php?rid=5161208&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5653253471qg121v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Prostate epithelial and stromal cells develop paracrine interactions, which may be responsible for the occurrence and progression
 of prostate pathologies. Strikingly, stromal cells exhibit pleiotropic effects on epithelial cell growth, ranging from stimulation
 to inhibition. Steroid hormone receptors are considered ligand-activated transcriptional factors. Moreover, it has been suggested
 that the human androgen receptor can also be activated in the absence of surrounding ligands such as growth factors and cytokines.
 Strong evidence suggests that cytokines may play an important role in ligand-independent activation of androgen receptor in
 prostate cancer cells. In our view, one of the most striking finding in the prostate cancer development process is the relationsh...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161208</comments>
            <pubDate>Sat, 20 Aug 2011 05:41:41 +0100</pubDate>
            <guid isPermaLink="false">5161208</guid>        </item>
        <item>
            <title>Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?</title>
            <link>http://www.medworm.com/index.php?rid=5161209&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc1j01m0511kvju1m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To investigate the sequential use of two tyrosine-kinase inhibitors (TKI), sorafenib (SOR) and sunitinib (SUN), in advanced
 renal carcinoma. We retrospectively analyzed the clinical outcome of 33 patients who had experienced progression or unacceptable
 toxicity after receiving either sorafenib or sunitinib and then switched to the other reciprocal agent. Progression-free survival
 (PFS) during the first TKI was similar regardless of drug with a median of 6&amp;nbsp;months in the SOR-SUN group (n&amp;nbsp;=&amp;nbsp;15) and 7.5&amp;nbsp;months in the SUN-SOR group (n&amp;nbsp;=&amp;nbsp;18). Interestingly, PFS during the second TKI was significantly longer in the SOR-SUN group as compared to the SUN-SOR
 group with median values of 11 and 3&amp;nbsp;months, respectively (P&amp;nbsp;=&amp;nbsp;0.0377; HR ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161209</comments>
            <pubDate>Fri, 19 Aug 2011 15:53:33 +0100</pubDate>
            <guid isPermaLink="false">5161209</guid>        </item>
        <item>
            <title>Clinical value of Tiam1–Rac1 signaling in primary gallbladder carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5161210&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg52rj98161m366n7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Tiam1–Rac1 signaling plays an important role in the migration, invasion and metastasis of tumor cells. The aim of the present
 study was to clarify the clinical value of Tiam1 and Rac1 expression in primary gallbladder carcinoma (PGC). Eighty-six PGC
 tissues were evaluated by immunohistochemistry for Tiam1 and Rac1 expression. The association of Tiam1 and Rac1 expression
 with clinicopathological characteristics and the univariate survival analysis for the influence of Tiam1 and Rac1 expression
 on the overall survival were analyzed. Tiam1 and Rac1 immunoreactivities were observed in 72 (83.7%) and 68 (79.1%) of the
 86 PGC cases, but not in the non-neoplastic gallbladder tissues, respectively. The tumors with the positive expression of
 Tiam1 and Rac1 more frequentl...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161210</comments>
            <pubDate>Fri, 19 Aug 2011 06:41:29 +0100</pubDate>
            <guid isPermaLink="false">5161210</guid>        </item>
        <item>
            <title>Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5161212&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp8427h521206h603%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Survival in patients with advanced non-small-cell lung cancer (NSCLC) has substantially improved. Long-term chemotherapy with
 epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) and other agents has been associated with long survival. We
 retrospectively examined the associations between overall survival (OS) and clinical variables in patients with advanced NSCLC
 who received at least one dose or course of outpatient chemotherapy in our institution. Of 360 patients who received first-line
 chemotherapy between January 1, 2004 and December 31, 2007, 185 subsequently received additional outpatient chemotherapy and
 175 underwent inpatient chemotherapy only. Of the 185 patients, 147 (79.5%), 96 (51.9%), and 60 (32.4%) received second-line,
 third-line, and fou...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161212</comments>
            <pubDate>Fri, 19 Aug 2011 06:41:28 +0100</pubDate>
            <guid isPermaLink="false">5161212</guid>        </item>
        <item>
            <title>Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5161211&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy50h04362448h177%2F</link>
            <description>This study
 highlights the combination of inflammatory CRP levels, Hb levels, and WBC count as the most important independent prognostic
 factor in predicting disease recurrence of patients with OSCC. LPI can be used as a pre-treatment inflammatory biomarker that
 may identify OSCC with a more aggressive biological phenotype of the disease and might be helpful for guiding further post-operative
 treatment in OSCC.
 
 
	Content Type Journal ArticleCategory Original PaperPages 1-13DOI 10.1007/s12032-011-0045-3Authors
		M. Grimm, Department of Oral and Maxillofacial Surgery, Plastic Operations, General Hospital, Breslauer Strasse 201, 90471 Nuremberg, GermanyM. Lazariotou, Department of Cardiac and Thoracic Surgery, University of Wuerzburg Hospital, Oberduerrbacher Strasse 6, 97080 Wuerzburg,...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161211</comments>
            <pubDate>Fri, 19 Aug 2011 06:41:28 +0100</pubDate>
            <guid isPermaLink="false">5161211</guid>        </item>
        <item>
            <title>Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study</title>
            <link>http://www.medworm.com/index.php?rid=5161213&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F75847m82n24546q8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To study the treatment outcomes of brain-only metastases from small-cell lung cancer (SCLC) at initial diagnose treated by
 chemotherapy with concurrent brain and thoracic radiotherapy (RT). From Jan 2004 to Jan 2009, 36 treatment-naïve SCLC patients
 with brain-only metastases in Sun yat-sen University were enrolled. Treatment contained initial EP chemotherapy with concurrent
 whole-brain radiotherapy (WBRT). EP regimen consisted of etoposide 100&amp;nbsp;mg/m2 IV d1-3, cisplatin 80&amp;nbsp;mg/m2 IV d1, repeated every 3&amp;nbsp;weeks. WBRT with total dose of 30&amp;nbsp;Gy in 10 fractions was started within 1&amp;nbsp;week from the beginning
 of chemotherapy followed by thoracic RT including 2&amp;nbsp;Gy once daily to a total dose of 60&amp;nbsp;Gy. Treatment responses were evaluated
 after 3...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161213</comments>
            <pubDate>Fri, 19 Aug 2011 06:41:27 +0100</pubDate>
            <guid isPermaLink="false">5161213</guid>        </item>
        <item>
            <title>Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=5161214&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fuk8727003207860x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;ATM protein kinase plays a critical role in maintaining genome integrity by activating a biochemical chain reaction that in
 turn leads to cell cycle checkpoint activation and repair of DNA damage. Cyclin D1 acts in regulating the G1 phase of the
 cell cycle. Experimental and clinical studies suggest them to be involved in transformation and tumour progression. To elucidate
 the role of ATM and cyclin D1 expression in sporadic breast cancer, we investigated the possible link between their RNA expression
 levels in ductal carcinoma and normal adjacent versus normal breast tissues measured by Taqman real-time PCR in 119 breast
 tissues. Results showed that cyclin D1 over-expressed in 51.4% of breast tumours, whereas ATM expression was down regulated
 in 55% of breast tumo...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161214</comments>
            <pubDate>Thu, 18 Aug 2011 06:01:11 +0100</pubDate>
            <guid isPermaLink="false">5161214</guid>        </item>
        <item>
            <title>An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors</title>
            <link>http://www.medworm.com/index.php?rid=5161215&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft80685u8018r5047%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Programmed cell death 4 (PDCD4) is a tumor suppressor that can inhibit tumorigenesis by suppressing activator protein (AP)-1
 activation and protein translation. Lost or decreased PDCD4 expression has been found in multiple types of human cancers,
 which was also associated with progression and metastasis of the tumors. However, the status and significance of PDCD4 in
 gastrointestinal stromal tumors have not been evaluated. In the present study, we examined the PDCD4 expression in a total
 of 63 gastrointestinal stromal tumor samples at both mRNA and protein levels by RT-PCR, western blot, and immunohistochemistry.
 We demonstrated that the expression of PDCD4 mRNA was diminished in 68% (17/25) of the tumor samples, and the level of PDCD4
 protein appeared to be decrea...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5161215</comments>
            <pubDate>Thu, 18 Aug 2011 06:01:09 +0100</pubDate>
            <guid isPermaLink="false">5161215</guid>        </item>
        <item>
            <title>Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status</title>
            <link>http://www.medworm.com/index.php?rid=5143406&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F32k55033651t42k4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Panitumumab is the first fully human monoclonal antibody targeting the epidermal growth factor receptor whose clinical use
 is limited to patients with a non-mutated KRAS status. The aim of this in vitro study was to evaluate whether the KRAS status might influence the cytotoxic and radiosensitizing efficacy of Panitumumab. Exponentially growing cancer cells (HT-29:
 KRAS wild-type, A549: KRAS mutant) were either treated with the monoclonal antibody alone in growth and proliferation assays or in combination with
 radiation in metabolic and colony-forming assays. For the assessment of ionizing radiation-induced DNA damage and to evaluate
 Panitumumab’s influence on DNA damage repair, the γH2AX foci assay was performed. Treatment with Panitumumab resulted in a
 concent...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5143406</comments>
            <pubDate>Sun, 14 Aug 2011 05:43:56 +0100</pubDate>
            <guid isPermaLink="false">5143406</guid>        </item>
        <item>
            <title>Erratum to: Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population</title>
            <link>http://www.medworm.com/index.php?rid=5131797&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F04006743q4254m84%2F</link>
            <description>Content Type Journal ArticlePages 1-1DOI 10.1007/s12032-011-0039-1Authors
		A. Daraei, Department of Biomedical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranR. Salehi, Department of Biomedical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranM. Salehi, Department of Biomedical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranM. H. Emami, Isfahan University of Medical Sciences, Isfahan, IranM. Janghorbani, Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, IranF. Mohamadhashem, Department of Biomedical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranH. Tavakoli, Isfahan University o...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5131797</comments>
            <pubDate>Fri, 12 Aug 2011 06:17:46 +0100</pubDate>
            <guid isPermaLink="false">5131797</guid>        </item>
        <item>
            <title>Combination of narrow band imaging (NBI) and autofluorescence imaging (AFI) videobronchoscopy in endoscopic assessment of lung cancer extension</title>
            <link>http://www.medworm.com/index.php?rid=5126133&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34t128374333tr63%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Both narrow band imaging (NBI) and autofluorescence imaging (AFI) are new techniques for the assessment of lung cancer. The
 major aim of this study was to investigate whether the combination of these two techniques improve sensitivity and specificity
 in the assessment of lung cancer extension. The study prospectively evaluated 118 patients with suspected lung cancer. All
 of the patients were examined using EVIS LUCERA SPECTRUM videobronchoscopy system. The narrow band imaging preceded autofluorescence
 imaging examination. In every patient, at least 1 but no more than 4 biopsies were taken from places visualized as pathologic,
 surrounding primary tumor, and at least 1 biopsy from places that appeared visually normal. Sensitivity, specificity, positive,
 and negative...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5126133</comments>
            <pubDate>Mon, 08 Aug 2011 19:55:34 +0100</pubDate>
            <guid isPermaLink="false">5126133</guid>        </item>
        <item>
            <title>Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis</title>
            <link>http://www.medworm.com/index.php?rid=5109073&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv44317477q83uw46%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;US Oncology Research Trial 9735 reported that TC improved overall survival when compared to doxorubicin and cyclophosphamide
 in early-stage breast cancer. Despite 61% grades 3–4 neutropenia in the TC arm, only 5% of patients developed febrile neutropenia
 (FN) without primary prophylactic GCSF (ppGCSF). TC has risen in popularity, particularly in older patients or in those where
 an anthracycline is contraindicated. Other studies examining the toxicity of TC without ppGCSF reported a higher incidence
 of FN between 23 and 46%. We reviewed our institutional experience with ppGCSF and the TC regimen. Women treated with adjuvant
 TC and pegfilgrastim at Roswell Park Cancer Institute were identified from the pharmacy database between 8/2006 and 11/2010.
 Patient characte...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5109073</comments>
            <pubDate>Fri, 05 Aug 2011 06:01:45 +0100</pubDate>
            <guid isPermaLink="false">5109073</guid>        </item>
        <item>
            <title>Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=5097202&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1g4512865w682244%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Rituximab (the chimeric anti-CD20 antibody) is widely used in the treatment of CD20 positive non-Hodgkin’s lymphoma (NHL).
 The response rate at relapse after repeated use in prior CD20 positive responders is lower than 50%. Several mechanisms can
 be responsible for rituximab resistance. CD20 negative relapses which transformed from CD20 positive aggressive and indolent
 forms of lymphoma can be the one of the reason of secondary resistance to rituximab. The authors report a case with combination
 of aggressive and indolent form of lymphoma who relapsed after 7&amp;nbsp;months from the last dose of rituximab therapy. CD20 transformed
 negative from positive in her relapsed disease. Patients with CD20 positive B cell NHL must rebiopsy after first line rituximab
 therapy i...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5097202</comments>
            <pubDate>Sun, 31 Jul 2011 05:40:52 +0100</pubDate>
            <guid isPermaLink="false">5097202</guid>        </item>
        <item>
            <title>DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy</title>
            <link>http://www.medworm.com/index.php?rid=5097203&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy8207171022t6288%2F</link>
            <description>This study aimed to investigate association between single-nucleotide polymorphisms (SNPs) of excision repair cross-complementing
 gene 1 (ERCC1), excision repair cross-complementing gene 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) with
 sensitivity of advanced non-small cell lung cancer (NSCLC) patients to platinum-based chemotherapy. A total of 89 NSCLC patients
 were recruited and treated with two cycles of platinum-based chemotherapy. DNA was extracted from peripheral lymphocytes for
 detection of SNPs of ERCC1 Asn118Asn, ERCC2 Lys751Gln, and XRCC1 Arg399Gln. The overall response rate of these patients was
 29.2%. There was no statistically significant difference of treatment response between the wild genotypes and the variant
 genotypes for the ERCC1 Asn118Asn and ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5097203</comments>
            <pubDate>Sun, 31 Jul 2011 05:40:51 +0100</pubDate>
            <guid isPermaLink="false">5097203</guid>        </item>
        <item>
            <title>miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver</title>
            <link>http://www.medworm.com/index.php?rid=5063448&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg215572x44568v17%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Many recent studies have shown the utility of microRNAs (miRs) as cancer-related biomarkers. The aim of the present study
 was to evaluate the correlation between miR-203 expression and prognosis of patients with hepatocellular carcinoma (HCC) and
 cirrhosis after liver transplantation (LT). Sixty-six HCC samples from patients who had undergone LT were examined for miR-203
 expression using quantitative reverse transcription–polymerase chain reaction. The data were correlated with clinicopathological
 parameters and prognosis. Patient survival was analyzed by the Kaplan–Meier method and log-rank test. Cox regression was used
 for multivariate analysis of prognostic factors. We found that miR-203 expression was low in tumor tissues of patients (n&amp;nbsp;=&amp;nbsp;16) with...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063448</comments>
            <pubDate>Sat, 23 Jul 2011 15:49:49 +0100</pubDate>
            <guid isPermaLink="false">5063448</guid>        </item>
        <item>
            <title>Comparative study of the immunohistochemical expression of tissue inhibitors of metalloproteinases 1 and 2 between clearly invasive carcinomas and “in situ” trophoblast invasion</title>
            <link>http://www.medworm.com/index.php?rid=5063449&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F020027w48p9758pg%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Tissue inhibitors of metalloproteinases (TIMPs) play an important role in extracellular matrix homeostasis by regulating MMP
 activity. Although they were initially considered inhibitors of tumor growth and metastasis, recently their role in cancer
 progression has been controversial. The aim of our study was to compare the immunohistochemical expression of TIMP1 and TIMP2
 between an uncontrollably invasive phenomenon (cancer) and an “in situ” process (trophoblast invasion) in an effort to assess
 any differential role of these molecules between these two distinct phenomena and therefore to understand better their contribution
 in cancer invasion and migration. We performed an immunohistochemical analysis of 50 carcinomas (colorectal, gastric, breast,
 pulmonary, a...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063449</comments>
            <pubDate>Sat, 23 Jul 2011 15:49:48 +0100</pubDate>
            <guid isPermaLink="false">5063449</guid>        </item>
        <item>
            <title>The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy</title>
            <link>http://www.medworm.com/index.php?rid=5063450&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh36055418664hql0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Epidermal growth factor receptor (EGFR) was expressed widely in NPC. The aim of this study was to investigate the difference
 of expression of EGFR and Ki67 in primary and recurrence of NPC to supply a micro-evidence of anti-EGFR targeted maintenance
 therapy for NPC. A retrospective review of 40 patients with clinical stages I–IV b was performed. Chemoradiation was included
 chemotherapy with fluorouracil plus cisplatin and irradiation for primary and lymph draining regions. All patients were verified
 tumor locoregional relapse with/or without distant metastasis by CT or MRI after combined CRT by primary and recurrence biopsies.
 The correlation between EGFR and Ki67 expression inspected by immunohistochemistry was analyzed. The difference of time to
 recurrence gro...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063450</comments>
            <pubDate>Fri, 22 Jul 2011 17:07:36 +0100</pubDate>
            <guid isPermaLink="false">5063450</guid>        </item>
        <item>
            <title>A novel prognostic model for extranodal natural killer/T-cell lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=5063452&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1672667483273564%2F</link>
            <description>This study aimed to devise a
 prognostic model specifically for extranodal NK/T-cell lymphoma, providing risk stratification in affected patients. A total
 of 146 patients newly diagnosed with extranodal NK/T-cell lymphoma were retrospectively analyzed. Independent predictors of
 survival were determined by Cox regression analysis. The estimated 5-year overall survival rate for all patients was 41.9%.
 Both the International Prognostic Index and Korean NK/T-cell lymphoma Prognostic Index were prognostic in univariate analysis.
 The majority of our patients were in the low-risk International Prognostic Index and Korean NK/T-cell lymphoma Prognostic
 Index category (with no or one adverse factor), but both of these two prognostic models had no discriminating power within
 the subgroup of the...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063452</comments>
            <pubDate>Fri, 22 Jul 2011 17:07:35 +0100</pubDate>
            <guid isPermaLink="false">5063452</guid>        </item>
        <item>
            <title>A preliminary study on the expression of tumor-associated glycoprotein-72 in human gliomas</title>
            <link>http://www.medworm.com/index.php?rid=5063451&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F97287116v02g6n76%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight tumor-associated glycoprotein, which is known to be overexpressed
 in various human tumors, but its expression in glioma tissues is unknown. Therefore, the aim of this study was to investigate
 whether TAG-72 is present in glioma and to evaluate the correlation between TAG-72 expression and the severity of the malignancy
 of this tumor. Immunohistochemistry and Western blot were used to investigate the expression of TAG-72 protein, respectively,
 in 152 patients with gliomas. There were 90 men and 62 women (mean age 50.6&amp;nbsp;±&amp;nbsp;11.8&amp;nbsp;years). Astrocytoma was found in 130 patients
 and glioblastoma in 22. No TAG-72 expression was found in the non-cancerous brain tissues. TAG-72 protein expressi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063451</comments>
            <pubDate>Fri, 22 Jul 2011 17:07:35 +0100</pubDate>
            <guid isPermaLink="false">5063451</guid>        </item>
        <item>
            <title>Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib</title>
            <link>http://www.medworm.com/index.php?rid=5063454&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd79k8761153630t4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor
 (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy
 and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese
 patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine
 their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response
 to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence
 interval, 1.042–...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063454</comments>
            <pubDate>Thu, 21 Jul 2011 18:08:10 +0100</pubDate>
            <guid isPermaLink="false">5063454</guid>        </item>
        <item>
            <title>Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery</title>
            <link>http://www.medworm.com/index.php?rid=5063453&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm6816h4u3485r805%2F</link>
            <description>In conclusion,
 we demonstrate a significant importance of the number of reinfused CD34+ cells on the time to platelet recovery.
 
 
	Content Type Journal ArticlePages 1-9DOI 10.1007/s12032-011-0029-3Authors
		J. S. Ungerstedt, Hematology Center, Karolinska University Hospital, R51, S-14186 Stockholm, SwedenE. Watz, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, SwedenK. Uttervall, Hematology Center, Karolinska University Hospital, R51, S-14186 Stockholm, SwedenB-M Johansson, Department of Clinical Immunology &amp; Transfusion Medicine, Karolinska University Hospital, Stockholm, SwedenB. E. Wahlin, Hematology Center, Karolinska University Hospital, R51, S-14186 Stockholm, SwedenP. Näsman, Center for Safety Research, Royal Institut...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063453</comments>
            <pubDate>Thu, 21 Jul 2011 18:08:10 +0100</pubDate>
            <guid isPermaLink="false">5063453</guid>        </item>
        <item>
            <title>Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production</title>
            <link>http://www.medworm.com/index.php?rid=5063455&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm62601272616pv25%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Arsenic trioxide (ATO) has shown anticancer activity against a variety of solid tumor models through induction of apoptosis,
 promotion of cellular differentiation, and inhibition of cellular invasive ability. The present study investigated the role
 of ceramide in regulating the invasive activity of hepatoma carcinoma HCCLM3 cells during ATO treatment. We found that ATO
 treatment inhibited HCCLM3 cell invasion and downregulated matrix metalloproteinase-9 (MMP-9) protein levels in a concentration-dependent
 manner. ATO also dose dependently induced the generation and accumulation of ceramide in HCCLM3 cells. Blockage of intracellular
 ceramide production through the inhibition of de novo ceramide synthesis or the hydrolysis of sphingomyelin increased the
 invasive abil...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5063455</comments>
            <pubDate>Tue, 19 Jul 2011 23:23:41 +0100</pubDate>
            <guid isPermaLink="false">5063455</guid>        </item>
        <item>
            <title>Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling</title>
            <link>http://www.medworm.com/index.php?rid=5052455&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb88u26713m45555m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cell surface transmembrane signaling receptors EGFR, HER3, and HER4 are activated by ligand-binding-mediated dimerization
 and phosphorylation. In contrast, HER2 amplification promotes signaling by increasing homo/heterodimerization and ligand binding.
 Trastuzumab or lapatinib therapy of HER2 amplicon-positive breast cancer cells induces growth inhibition and intracellular
 growth pathway signaling modulation. The mechanism(s) by which trastuzumab, an IgG1 humanized antibody, induces modification
 of cell signaling upon binding to an extracellular determinant on a ligand-less “receptor” membrane protein remains unexplained.
 Using immune detection methodology comprised of antibodies detecting three distinct domains of HER and five tyrosine/threonine
 phosphorylatio...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052455</comments>
            <pubDate>Mon, 18 Jul 2011 15:53:46 +0100</pubDate>
            <guid isPermaLink="false">5052455</guid>        </item>
        <item>
            <title>Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine</title>
            <link>http://www.medworm.com/index.php?rid=5038113&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu11271u3236531k8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Homeostasis-driven proliferation of T cells is an important means of reconstituting T-cell-dependent immunity after lymphodepletion
 regimens, such as chemotherapy or radiotherapy. Immune-reconstituted mice that receive a tumor vaccine mount more efficient
 anti-tumor immune responses compared with control mice. In the present study, we evaluated the anti-tumor immune responses
 in immune-reconstituted mice vaccinated with inactivated leukemia cells and explored the mechanisms underlying these immune
 responses. Test C57BL/6 mice were lymphodepleted by irradiation and immune-reconstituted with naïve mouse spleen lymphocytes.
 Mice were then injected with an inactivated FBL-3 tumor cell vaccine and challenged with FBL-3 tumor cells. Anti-tumor responses
 were evaluated ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5038113</comments>
            <pubDate>Fri, 15 Jul 2011 05:55:09 +0100</pubDate>
            <guid isPermaLink="false">5038113</guid>        </item>
    </channel>
</rss>

